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ABSTRACT: 
 
Acute Lung Injury (ALI) is a pulmonary inflammatory disorder resulting in respiratory 
failure that is initiated by a number of different insults to the lung. Despite very high 
mortality, there are still no effective pharmacological therapies for this disease, and the 
main supportive treatment, mechanical ventilation (MV), can further lung injury and 
inflammation, contributing to ALI progression.  
The overall objective of this work was, therefore, to broaden the knowledge of ALI 
pathophysiology in an attempt to improve outcomes for this disorder. To this end, the roles 
of two key players in the disease process were evaluated, namely: i) lung surfactant, a 
material essential for minimizing the work of breathing and for pulmonary immuno-
modulation, and ii) matrix metalloproteinase 3 (MMP-3), protease involved in the 
inflammatory response associated with ALI. The experimental approach consisted of 
exposing mice to different models of ALI, in order to investigate: i) the effects of 
exogenous surfactant administration on lung inflammation and injury progression 
associated with MV, ii) the role of MMP-3 in the pulmonary inflammatory response 
associated with ALI, and iii) the potential interactions between MMP-3-related 
inflammatory changes, surfactant function, and pulmonary mechanics in ALI.  
The results demonstrated that exogenous surfactant treatment did not impact inflammatory 
outcomes of ALI that are associated, clinically, with mortality. Further research is therefore 
required to improve such potential therapy. The data also illustrated the contribution of 
MMP-3 to the pulmonary inflammation associated with ALI, specifically in female mice. 
Furthermore, the complexity of the interactions between lung inflammation, surfactant 
function, and mechanics of the lung was demonstrated.  
Overall, this evidence underscored the challenges faced in the treatment of ALI; 
nonetheless, a broader knowledge of ALI complex pathophysiology will be beneficial to 
the design of new therapies and the improvement of ALI outcomes. 
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CHAPTER 1:  
General introduction and literature review 
 
  
2 
 
1.1. General overview  
Most of the metabolic processes taking place in the human body require oxygen and 
generate carbon dioxide as a waste product that needs to be eliminated. The lung is the 
organ responsible for exchange of gases, providing oxygen to the blood for delivery to all 
systems in the body, and allowing for carbon dioxide removal to the external environment 
[1]. This process, essential for life, can become impaired as a result of a variety of diseases 
affecting the lung, such as asthma, chronic bronchitis, fibrosis and, central to this thesis, 
acute lung injury. 
Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is a pulmonary 
disorder with a complex pathophysiology and no proven therapeutic option available for 
its treatment [2]. Throughout the years, understanding of this disorder has been hampered 
by the multiplicity of lung insults potentially causing ALI/ARDS, the wide range of patient 
population, which includes both pediatric and adult subjects, and a complex disease 
progression [3, 4]. Two aspects of its pathophysiology and treatment support, however, are 
common to all patients with ALI/ARDS: i) the use of mechanical ventilation, necessary to 
support impaired gas exchange, and ii) the development of an overwhelming pulmonary 
inflammatory response. 
As explained more extensively throughout this doctoral thesis, persisting and 
overwhelming lung inflammation negatively affects lung function, and has been shown to 
correlate with poor prognosis and outcome in patients with ALI/ARDS [5, 6]. This scenario 
is further aggravated by the effects of mechanical ventilation on the injured lung. 
Mechanical ventilation has been shown to alter lung surfactant [7], a substance lining the 
inner pulmonary surface, with biophysical and immune-modulatory properties essential for 
lung function [8, 9]. Ventilation-induced impairment of lung surfactant leads to impaired 
lung function [10], which can often be rescued by administration of exogenous surfactant 
[11]. The effects of mechanical ventilation, however, are not limited to surfactant, as 
ventilation can further pulmonary inflammation, and participate in the progression toward 
the development of an inflammatory response in the systemic circulation [12–14]. These 
events can, ultimately, affect distal organ function causing multi-organ failure, the major 
cause of death in ALI/ARDS patients [15, 16]. 
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In light of these issues, the first scientific problem addressed in chapter two is related to 
the assessment of a lung-targeted strategy aimed at mitigating the effects of 
ventilation on the inflamed lung. The strategy of interest is exogenous surfactant 
administration. The objective of chapter two is to determine whether exogenous surfactant 
administration can mitigate ventilation-induced pulmonary and systemic inflammation, in 
different mouse models of ALI/ARDS. 
The second aspect highlighted by the lack of suitable treatment is the need for a better 
understanding of ALI/ARDS pathophysiology, specifically focused on identifying key 
mediators in the pulmonary inflammatory response that may serve as future potential 
therapeutic targets. Among the multiple mediators involved in ALI/ARDS, chapter 3 
focuses on the protease matrix metalloproteinase-3 for its role in inflammation and 
inflammatory diseases [17]. The objective of chapter three is to assess the role of matrix 
metalloproteinase-3 in the development of the pulmonary inflammation associated with 
ALI/ARDS. The results of matrix metalloproteinase-3 contribution to inflammation in two 
different mouse models of lung injury prompted the investigation of further aspects of 
disease development. 
Chapter four focuses on the examination of the potential role of matrix 
metalloproteinase-3 in the interplay between pulmonary inflammation and lung 
function. The objective of chapter four is in fact to investigate whether such protease, 
mediator of lung inflammation, can affect the surfactant system and overall lung function. 
The remaining of this first chapter provides general information on lung structure and 
function, and illustrates in greater detail the pathophysiology of ALI/ARDS, touching on 
the inflammatory response, lung surfactant, and matrix metalloproteinase-3, before closing 
with a brief description of the animal models available for the study of this disorder. 
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1.2. Lung function and structure 
The primary function of the lung is gas exchange. During breathing, oxygen entering the 
lungs diffuses into the blood, while carbon dioxide diffuses from the blood into the lung to 
be exhaled in the external environment. Lung function is facilitated by a number of 
anatomical features, namely the presence of an extremely large pulmonary surface area 
available for diffusion, close proximity of the inhaled air to blood vessels at the alveolar 
level, and the very low thickness of the alveolo-capillary barrier through which oxygen and 
carbon dioxide diffuse [1].  
Such anatomical features are the final result of a tree-like structure that starts at the nose 
and mouth, and proceeds within the thoracic cavity via a semi-flexible tube, the trachea, 
which divides into left and right main primary bronchi. Each bronchus branches multiple 
times into progressively narrower and shorter bronchi/bronchioles down to the terminal 
bronchioles, thereby generating a very large number of conducting airways. The process 
of subsequent divisions continues further into the distal regions of the lung, until millions 
of individual lung units, known as alveoli, generate a very large surface area suitable for 
gas exchange. Diffusion of oxygen and carbon dioxide is also favored by the vast network 
of capillaries wrapped around the alveoli, with the capillary endothelial cells laying in very 
close proximity to the epithelial cells of the alveoli [1].  
As mentioned, epithelial cells form the alveolar wall; precisely, alveoli are mainly made of 
flat, squamous type I alveolar epithelial cells and some cuboidal type II epithelial cells. 
The type II cells produce and secrete pulmonary surfactant at the air-liquid interface [18]. 
Surfactant, a protein-lipid mixture, is very important for reducing the surface tension in the 
alveoli, thereby optimizing lung compliance and facilitating the work of breathing [8]. In 
addition to type I and type II epithelial cells, some resident alveolar macrophages (AM) are 
found within the alveolar space, where they act as a first line defense against pathogens 
and participate in surfactant metabolism [19, 20]. 
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1.3. Lung mechanics 
In addition to the structure of the lung, the process of ventilation is important for gas 
exchange. Ventilation refers to the process by which a volume of air, known as tidal 
volume, enters and leaves the lung with each breathing cycle. The mechanics of this 
process are closely linked to the properties of the lungs and those of the thoracic cavity in 
which the lungs are located. Within this enclosed space, the base of the lungs comes in 
contact with the diaphragm, a dome-shaped muscle that separates the lungs from the 
abdominal contents. Pleural membranes surround the outer surface of each lung and line 
the inside of the chest wall, forming a thin intra-pleural space that is normally filled with a 
small volume of fluid. The intra-pleural space provides connection between the lung and 
the chest wall, and given the natural tendency of the chest wall to expand and the lung to 
collapse, this space has a slightly sub-atmospheric pressure or, in other words, a negative 
pressure [1].  
During inspiration, contraction of the inspiratory muscles (diaphragm and external 
intercostals) causes an increase in the volume of the thoracic cavity. With the increase in 
volume, the negative intra-pleural pressure becomes more negative leading to the 
expansion of the lung and a fall in alveolar pressure to a slightly sub-atmospheric value. 
This pressure gradient promotes flow of air from the atmosphere to the alveoli. In tidal 
breathing (non-exertional), expiration, unlike inspiration, is a passive process resulting 
from the relaxation of the inspiratory muscles, with subsequent decrease in the thoracic 
and lung volumes. These changes affect the alveolar pressure, now slightly greater than 
atmospheric pressure, providing the driving force necessary for air to flow from the alveoli 
back to the atmosphere [1].  
The work of breathing can be affected by two main factors: the resistance to airflow within 
the conducting airways and the distensibility of the lung tissue. In healthy subjects, the 
medium to larger airways offer a negligible degree of resistance to the airflow. Narrowing 
of these airways, however, as a result of bronchial constriction or obstruction such as in 
asthma, will increase the resistance and impair airflow [21]. 
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The distensibility of the lung tissue, known as compliance, refers to the ability of the lung 
to inflate and stretch during inspiration. Lung compliance is an indicator of the stiffness of 
the lungs, and it is defined as volume change per unit pressure change [1]. Two principal 
factors can influence compliance: the elastic properties of the lung and the surface tension 
of the alveolar lining fluid. The elastic properties can be described essentially as the 
tendency of the lung to recoil to the resting volume after distention. Lung elasticity arises 
from the elastin and collagen fibers in the pulmonary tissue, and any alteration of these 
fibers can cause changes in lung compliance [1]. As mentioned, compliance is also 
influenced by the surface tension arising from attractive forces between water molecules 
at the air-liquid interface within the alveoli. In healthy lungs, surface tension has very low 
values attributable to the presence of a material lining the alveoli called pulmonary 
surfactant. Secreted by alveolar type II cells at the air-liquid interface, lung surfactant is a 
protein-lipid mixture that lowers surface tension, thereby stabilizing the alveoli and 
reducing the work of breathing [8, 22]. Whole lung compliance is therefore strongly 
affected by the presence of a functioning surfactant system. The relationship between an 
impaired surfactant system and consequently poor lung compliance is most evident in a 
disease called the neonatal respiratory distress syndrome, where preterm infants are born 
with insufficient amounts of surfactant and struggle to breath [23]. Alterations of the 
surfactant system in a mature lung can occur in the acute respiratory distress syndrome, 
which is the focus of this thesis.  
A more detailed overview of surfactant composition, function and alterations during 
disease will be provided in the following sections of this thesis. 
 
1.4. Lung insults: the Acute Lung Injury / Acute Respiratory Distress Syndrome 
(ALI/ARDS) paradigm. 
1.4.1. ALI/ARDS definition 
This thesis focuses on the clinical problem of acute lung injury (ALI) and on ALI’s more 
severe form, the acute respiratory distress syndrome (ARDS). An adult respiratory-distress 
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syndrome was first described in 1967 by Ashbaugh in twelve adults presenting with acute 
onset of rapid breathing, hypoxia, and poor lung distensibility [24]. The extensive research 
that followed improved the knowledge of this disease’s pathophysiology, leading to a 
renaming of the disease to acute respiratory distress syndrome and a clear clinical definition 
in 1994 by the American-European Consensus Conference. ARDS and ALI were defined 
as acute in onset and characterized by bilateral radiologic infiltrates with no evidence of 
heart failure, and hypoxemia, as determined by the ratio of arterial partial pressure of 
oxygen (PaO2) to fraction of inspired oxygen (FIO2). Specifically, ALI was defined by a 
PaO2/ FIO2 ≤ 300mmHg, while the cut off for the more severe ARDS was a PaO2/ FIO2 ≤ 
200mmHg [25]. In more recent years, some of the limitations of this definition have been 
addressed with the updated “Berlin definition”, which has removed the term ALI and 
instead distinguishes between three mutually exclusive ARDS subgroups (mild, moderate, 
or severe ARDS) based on the severity of the hypoxemia [26]. While this new definition 
constitutes an improvement to the clinical practice allowing for better stratification of 
patients in clinical trials, it poses some challenges in its application to animal models of 
lung injury since there is no reference to underlying pathophysiology. The terminology 
acute lung injury, instead, traditionally includes a broader spectrum of the disease, 
encompassing both patients and experimental models. For this reason, the term ALI will 
be used to refer to the acute lung injury/acute respiratory distress syndrome throughout the 
remainder of this thesis. 
A broadly accepted definition of this disease has allowed for the collection of useful 
epidemiological information. Recent estimates suggest an ALI incidence of approximately 
60-80 new cases per 100,000 person-years in the United States [4, 27]. Importantly, 
mortality from ALI is still very high at 40%, with distal organ failure, rather than 
respiratory failure, being the main cause of death for these patients [15, 16, 28].  
1.4.2. ALI overview 
Despite a relatively simple clinical definition based on physiological parameters, ALI is a 
complex pulmonary disorder characterized by decreased compliance, persistent and 
elevated lung inflammation, a high mortality, and no available therapeutic options [29–31]. 
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After many years of clinical and basic research, many aspects of ALI pathophysiology are 
still elusive and challenge the development of effective pharmacological therapies. To add 
to the complexity, disease progression is associated with the development of systemic 
inflammation and multi-organ failure which is, as previously mentioned, the most common 
cause of death in ALI [15, 32].  
Affecting patients of all ages, ALI is initiated by a variety of lung insults of different origin 
[2]. For example, potential threats and pathogens can come from the external environment, 
to which the lung is continuously exposed [33, 34]. On the other hand, the lung receives 
the entire cardiac output through its vasculature and can therefore be affected indirectly by 
damage-associated molecules or invading organisms found in the pulmonary circulation 
[33, 34]. In most cases, the lung can manage and effectively clear such threats. On occasion, 
however, the host response to a lung insult can become maladaptive. As a result, patients 
with ALI present with lung edema, altered pulmonary surfactant, decreased compliance 
with an associated hypoxemia, and a sustained pulmonary inflammatory response [2, 35, 
36]. 
The progressive hypoxemia affecting these patients ultimately requires the use of 
mechanical ventilation (MV), the main supportive treatment for this disorder. Even though 
essential, MV can contribute to lung injury and inflammation, thereby promoting ALI 
progression [12]. The role of MV in ALI became strongly evident in a large, multi-center 
randomized clinical trial conducted in 2000 [37]. In this study, the ARDS Network assessed 
the effect of ventilation using different tidal volumes in patients with ALI. Patients received 
MV with either a ‘conventional’ tidal volume (Vt=12mL/kg predicted body weight) or a 
low tidal volume (Vt=6mL/kg predicted body weight) strategy. The trial was stopped early 
due to the significantly lower mortality in the low Vt group (31.0%) compared to the group 
receiving conventional Vt ventilation (39.8%) [37]. The underlying pathophysiological 
mechanism responsible for such outcome was suggested to stem from the effects of MV 
on the inflammatory response in ALI. An earlier clinical study by Ranieri et al. had in fact 
shown that, at 36 hours post randomization, more injurious ventilation strategies caused 
greater increases in both pulmonary and systemic inflammation in ALI patients, compared 
to concentrations at study entry and in patients ventilated with lung-protective MV [12]. 
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Overall, these clinical studies have highlighted that MV is a potential contributor to disease 
progression, by enhancing lung inflammation and leading to a systemic inflammatory 
response and peripheral organ failure. As such, MV could represent an ultimately effective 
target in ALI treatment. 
Additionally, this evidence shifted the focus from oxygenation, the traditional “clinical 
outcome” of patients with ALI/ARDS, to inflammation, as it became clear that a persistent, 
excessive lung inflammatory response is the culprit for disease progression [5, 6]. In this 
respect, Meduri et al. demonstrated that at the onset of ARDS, non-survivors had 
significantly higher pulmonary inflammatory mediators (i.e. IL6, IL8, TNF-α) levels than 
survivors, stressing the association between lung inflammation and disease outcome [6].  
Lastly, the evidence of a central role of inflammation in ALI would suggest that a lung-
targeted treatment, aimed at reducing pulmonary and systemic inflammation, could be 
extremely beneficial and more effective than strategies merely aimed at improving 
oxygenation. In this sense, exogenous surfactant administration is a lung-targeted 
treatment whose role in affecting the inflammatory response associated with ALI has been 
insufficiently characterized. Moreover, the study of key mediators of pulmonary 
inflammation (such as, for example, matrix metalloproteinase-3) could help identify 
new potential therapeutic targets for this disorder.  
1.4.3. Treatment of ALI  
Treatment of ALI is based on supporting gas exchange through MV, careful monitoring 
and stabilization of these critically ill patients, and management of the initiating insult 
when possible [38]. Unfortunately, no pharmacological treatment is yet available for this 
disorder, and even though many therapies have been promising experimentally, they have 
failed to improve outcomes clinically [39]. Among these, exogenous surfactant 
administration led to exciting improvements in oxygenation and compliance for ALI 
patients in Phase 2 trials and smaller Phase 3 trials [40, 41]. This treatment, however, did 
not appear to improve mortality in more recent, larger Phase 3 trials, possibly due to 
surfactant administration occurring too late in the paradigm of ALI development [40]. A 
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more in depth description of surfactant in ALI pathogenesis and treatment will be described 
in section 1.6. 
To date, the only approach shown to reduce mortality in ALI is the use of low tidal volume/ 
protective MV, likely due to lower pulmonary and systemic inflammation elicited by this 
strategy compared to higher Vt ventilation [37]. Since ALI is characterized by a persistent, 
excessive pulmonary inflammatory response [42, 43], anti-inflammatory treatments such 
as corticosteroids, statins and activated protein C could theoretically decrease mortality. 
The results from clinical trials however have been disappointing, showing no clear benefits 
of such treatments [44, 45]. It is therefore imperative to expand our knowledge of ALI 
pathophysiology and the associated inflammatory response, as well as to re-examine some 
of its treatments, in order to effectively interfere with disease progression and improve 
mortality.  
In summary, examination of the clinical studies performed to date suggest that ALI, 
although defined by physiological criteria, is a complex inflammatory disease in which its 
essential therapeutic intervention (MV) can actually contribute to disease progression. 
Despite the complex pathophysiology of ALI, recent animal and clinical studies have 
started to provide insight into the development of this disease. The current state of 
knowledge, and areas requiring further research, are described below with a specific focus 
on inflammation.  
 
1.4.4. Development of ALI: the ALI paradigm 
The current model for ALI development and progression, based on clinical, in vivo, and in 
vitro studies, is shown in figure 1.1. Briefly, the model illustrates how multiple insults (or 
hits) to a normal lung can lead to the development of ALI, and exemplifies the disease 
progression from lung injury to multi-organ failure, which is the main cause of death for 
ALI patients. More detailed information on the different steps in the multiple hit paradigm 
of ALI is provided in the upcoming sections.  
 
11 
 
 
 
Figure 1.1: Multiple hit paradigm of ALI development. 
 
1.4.4.1. Primary insults and ALI pathogenesis  
In the multiple hit paradigm of ALI, a normal lung is first exposed to an initiating or 
primary insult, which can be classified as either direct or indirect (Fig. 1.1) [2]. Indirect 
insults such as sepsis or trauma primarily affect the pulmonary vasculature, given the 
presence in the circulation of pathogens and inflammatory molecules from various 
potential sources. On the other hand, insults such as pneumonia or gastric acid aspiration 
represent direct injuries to the lung, and are the main focus of this thesis [2]. Numerous 
animal studies have shown that such direct injuries cause greater damage to the alveolar 
epithelium, and a more robust inflammatory response within the alveolar space compared 
to indirect insults [33, 46]. Overall, the response of the lung to any insult is a rather 
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complicated process involving a multitude of soluble mediators, multiple cells types, and 
a complex integration of intracellular pathways. For this reason, a simplification of the 
major pathophysiological steps involved in this disease is necessary to better understand 
ALI. 
Following the initial lung insult, the disruption of the alveolo-capillary barrier allows the 
abnormal leakage of a protein-rich edema into the alveolar space [29, 47]. This, in turn, 
inhibits surfactant function [48] and leads to a profound decrease in lung compliance [49]. 
Importantly, alveolar macrophages and, to some extent, epithelial cells respond to the 
injurious event by mounting an inflammatory response within the alveolar space [50]. Up-
regulation of pulmonary cytokines and chemokines results in the recruitment of 
polymorphonuclear neutrophils (PMNs), cells of the innate immune system that are first 
responders in tissue injury and infection [51]. While this initial inflammatory response is a 
homeostatic process important for injury resolution, the severity and persistence of 
inflammation in ALI can cause tissue injury, impair effective resolution, and correlate with 
poor outcomes. Occurrence of the latter processes may be promoted if the lung is exposed 
to a secondary insult. 
1.4.4.2. Secondary insult, systemic inflammation and   
 multi-organ failure 
The elevated pulmonary inflammation, alveolar flooding and surfactant alterations that 
follow a primary insult make the lung susceptible (predisposed lung) to the effects of other 
secondary insults, such as sepsis, trauma or, most commonly, mechanical ventilation (Fig. 
1.1). As mentioned earlier, decreased compliance and hypoxemia are hallmarks of ALI 
[25], and MV is necessary to support gas exchange. The contribution of MV as a secondary 
insult has been extensively highlighted in both clinical studies and animal models of lung 
injury [12, 14, 52, 53], many of which have also shed light on the three different ways MV 
participates in ALI progression.  
First, MV contributes to lung surfactant inactivation, with consequent alveolar collapse and 
worsening lung compliance [7, 54]. Second, due to the overstretching of the more aerated 
and compliant alveolar units, MV causes increased release of inflammatory mediators, 
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thereby exacerbating lung injury [55–57]. Third, ventilation itself is an important 
contributor in ALI progression toward systemic inflammation (Fig. 1.1) [13, 58].  
A vast body of experimental evidence has in fact shown that MV promotes the de-
compartmentalization of pulmonary inflammatory mediators into the systemic circulation, 
and that exacerbation of pulmonary inflammation by MV enhances the development of 
systemic inflammation [58–60]. Importantly, the severity of the systemic inflammatory 
response correlates with mortality in ALI [37]. Inflammatory molecules in the circulation 
are, in fact, biologically active and exert a pathogenic role on extra-pulmonary organs (i.e., 
liver and kidneys) ultimately leading to multi-organ failure [14, 52, 61–63]. An interesting 
study from our lab has in fact demonstrated that circulating inflammatory mediators 
released from injured lungs can activate distal cell populations, namely mouse liver 
endothelial cells and leukocytes, leading to a pro-inflammatory and pro-adhesive 
phenotype in these cells [64]. 
Since inflammation is a crucial component of ALI pathophysiology, an overview of the 
inflammatory response associated with ALI is necessary, before addressing in greater 
details the specific variables manipulated for the study of lung injury in this thesis. 
1.5. Inflammation and inflammatory mediators in acute lung injury 
As mentioned above, inflammation plays a central role in ALI. Inflammation is a complex, 
highly regulated adaptive response to tissue injury or infection, mounted to re-establish 
homeostatic conditions. The inflammatory response involves a variety of cellular and 
soluble mediators cooperatively working to eliminate the detrimental stimuli, thereby 
progressing toward phases of resolution and tissue repair [65]. Sometimes, however, for 
reasons that are not yet clear, the inflammatory process persists, becomes maladaptive, and 
may lead to organ injury and dysfunction as in the case of ALI.  
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1.5.1. Cellular components in the inflammatory process  
Among the different cell types participating in the inflammatory process, neutrophils are 
particularly relevant in the settings of ALI. Neutrophils are recruited to the injured lung 
and migrate into the air space shortly after a primary insult [51]. These cells are essential 
players in the innate immune response to injury and/or infection, and within the alveolar 
environment these cells can contribute to the development of ALI through the release of 
pro-inflammatory cytokines and production of reactive oxygen species [51, 66]. Moreover, 
activated neutrophils can secrete potent proteolytic enzymes, such as elastase, collagenase 
(i.e., matrix metalloproteinase-8) and gelatinases (i.e., matrix metalloproteinase-9), 
potentially responsible for alterations of the lung extracellular matrix [66]. The pathogenic 
role of neutrophils in ALI has been shown in animal models of lung injury [67, 68]; 
moreover, pulmonary accumulation and persistence of neutrophils appear to correlate with 
disease severity in patients with ALI [69]. Nonetheless, the evidence that neutropenic 
patients can develop lung injury as well [70], suggests that other cell populations may be 
involved in ALI. In fact, important contributors to this elaborate inflammatory response 
are also the parenchymal cells, namely endothelial cells, alveolar epithelial cells, 
fibroblasts, and the alveolar macrophages [50].  
As a first line of defense, the alveolar macrophages phagocytose pathogens and dead cells, 
can secrete anti-microbial peptides, and release proteases such as matrix metalloproteinases 
(including matrix metalloproteinase-3), thereby orchestrating the inflammatory and 
immune response, and contributing to the later reparative phase [71]. Additionally, alveolar 
macrophages can also release a variety of soluble mediators of inflammation, 
proteinaceous and/or lipidic in nature, responsible for many of the pathophysiological 
events occurring in ALI, including neutrophils recruitment [71].  
Migration and influx of leukocytes to the injured lung is also facilitated by the activated 
endothelium, which expresses surface adhesion molecules necessary for cell to cell 
interaction [72]. Epithelial cells participate to the immune response in ALI through the 
secretion of collectins (SP-A, SP-D) associated with surfactant and, additionally, via the 
release of inflammatory mediators (i.e. IL-1β, IL-8, TNF-α) in response to multiple stimuli, 
including stretch associated with MV [73–76].  
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1.5.2. Overview of soluble inflammatory mediators 
In addition to the cellular component, soluble mediators are a second key pathological 
feature in the development and progression of ALI. Following insults to the lung (Fig. 1.1), 
a broad variety of pro- and anti-inflammatory molecules are released from the 
aforementioned cellular sources within the lung and in the bloodstream. For the sake of 
brevity, only inflammatory signals relevant to this thesis will be reviewed in this section. 
Mediators of interest include: i) cytokines, ii) chemokines, and iii) lipid mediators. A list 
of such mediators with an indication of their main respective biological functions is given 
in Table 1.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Inflammatory Mediators Biological Activity 
Cytokines  
G-CSF Granulocyte survival/growth 
GM-CSF 
Host defense; 
granulocyte/monocyte/AM survival & 
growth  
IL-1β 
Pro-inflammatory; fever; neutrophil 
migration 
IL-6 
Pro-inflammatory; acute-phase 
response; leukocytes 
growth/differentiation 
IL-10 Dual role; pro- and anti- inflammatory 
IL-13 
Anti-inflammatory; asthma and allergic 
disease 
TNF-α 
Pro-inflammatory; hypotension/shock; 
cell cytotoxicity; fever 
Chemokines  
(alternative name) 
 
Eotaxin (CCL11) 
Pro-inflammatory; chemoattractant for 
eosinophils & basophils; allergic 
airways inflammation 
IP-10 (CXCL10) 
Pro-inflammatory; chemoattractant for 
activated T cells 
KC (CXCL1) 
Pro-inflammatory; chemoattractant for 
neutrophils 
LIX (CXCL5) 
Pro-inflammatory; chemoattractant & 
activator of neutrophils 
MCP-1 (CCL2) 
Pro-inflammatory; chemoattractant for 
monocytes 
MIP-2 (CXCL2) 
Pro-inflammatory; neutrophils 
chemoattractant/activator  
Lipid Mediators  
8-Isoprostane Marker of oxidative stress 
Leukotriene B4 
Pro-inflammatory; neutrophils 
chemoattractant/activator 
Prostaglandin E2 
Inflammation; vascular tone & 
permeability 
Thromboxane A2 
Pro-inflammatory; neutrophils 
chemoattractant/activator 
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Table 1.1: Summary of inflammatory mediators involved in ALI and most relevant in this 
thesis. KC, MIP-2 are considered murine equivalent of human IL-8. For further 
information, see Bathia M. et al. [43], Puneet P. et al. [77], and “Principles of internal 
medicine”, Harrison, 15th edition [78]. AM, alveolar macrophages. 
G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte-macrophage 
CSF, IL-6 = interleukin-6, IP-10 = interferon-γ-induced protein 10, KC = keratinocyte 
chemoattractant, LIX = lipopolysaccharide-induced CXC chemokine, MCP-1 = monocyte 
chemotactic protein-1, MIP-2 = macrophage inflammatory protein 2 and TNF-α = tumor 
necrosis factor-alpha. 
 
1.5.2.1. Cytokines and chemokines 
Cytokines and chemokines are small proteins secreted by immune and non-immune cells. 
Once released in the extracellular environment, cytokines will affect the activity and 
function of other, target cells [65]. Chemokines work as chemoattractant and activators of 
leukocytes, and are generally classified based on the position of the first two cysteine 
residues at the N-terminal: CC chemokines for adjacent residues, CXC if an amino acid 
separates them [77]. Together, cytokines and chemokines coordinate the inflammatory 
response through cell activation, changes in gene expression, and recruitment of 
inflammatory cells to the site of injury. These events are extremely significant in the 
pathogenesis of ALI, where increases of chemokine levels in alveolar fluid lead to massive 
recruitment and infiltration of neutrophils, potentially contributing to lung dysfunction [42, 
66]. In the multiple hit paradigm of ALI development, changes in pulmonary cytokine and 
chemokine levels are induced at first by a primary insult of variable nature [2]; invariably, 
however, MV is applied to the predisposed lung contributing to overwhelming cytokine 
release. Numerous experimental studies confirm the exacerbation of lung inflammation by 
MV and point out the ventilation-induced de-compartmentalization of mediators such as 
TNF-α, IL-8, MCP-1 in the systemic circulation, with consequent development of distal 
organ failure [13, 58, 60, 61, 79]. It appears, therefore, that alterations of the inflammatory 
milieu resulting from MV can worsen ALI outcomes. The pathogenic role of cytokines and 
chemokines in ALI is in fact substantiated by clinical evidence that elevated lavage and 
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plasma levels of IL-6, TNF-α, IL-1β, and IL-8 correlate with disease gravity and poor 
outcomes in these patients [6, 12, 80–82]. Importantly, the concentration of these pro-
inflammatory cytokines was found persistently elevated in the lung of non-survivors, while 
ALI survivors observed lower IL-6, TNF-α, IL-1β, and IL-8 levels at the onset of ALI, and 
over the course of the disease [6]. Overall, this evidence indicates the necessity to modulate 
pulmonary and systemic cytokine/ chemokine levels in order to improve ALI outcomes.  
1.5.2.2. Lipid mediators in ALI  
The complex inflammatory scenario associated with ALI is not limited to the above-
mentioned small, protein mediators, but also includes lipid mediators of inflammation 
(Table 1.1). Lipid mediators, or eicosanoids, are derived from the metabolism of 
arachidonic acid by different enzymes: the cyclooxygenases pathway leads to the 
production of mediators such as isoprostanes, prostaglandin E2 (PGE2) and thromboxane 
A2 (TXA2), while the activity of lipoxygenases generates, among others, leukotriene B4 
(LTB4) [83]. The contribution of these mediators to ALI pathogenesis can be inferred by 
both clinical and experimental data. 
Elevated concentrations of leukotrienes have been detected in lavage samples from 
ALI/ARDS patients [84]; moreover, LTB4 levels have been shown to correlate with the 
occurrence of lung injury in trauma patients [85]. Eicosanoids play a role in vascular tone, 
activation and permeability, and serve as potent chemoattractants and activators for 
neutrophils. In this regard, Zarbock et al. have demonstrated that TXA2 is responsible for 
the recruitment and accumulation of neutrophils to the injured lung in a mouse model of 
acid-induced ALI [67]. Moreover, experimental work performed by Jaecklin et al. has 
shown the pathogenic role of circulating lipid mediators in a model of ventilation-induced 
lung injury. The group observed that, when perfused in the pulmonary circulation of 
recipient mice, lung-derived mediators isolated from mice with ventilation-induced lung 
injury could worsen permeability and compliance of recipient mice ventilated with non-
injurious modes of MV [86]. Subsequent analysis of these soluble mediators revealed their 
protein and lipid nature, thereby strengthening the role of cytokines, chemokines and 
eicosanoids in ALI pathogenesis.  
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1.5.3. Targeting inflammation as a therapy for ALI 
Despite the convincing evidence that overwhelming inflammation is an important 
pathophysiological feature contributing to the progression of ALI, interfering with this 
process has not been successful to date. For example, strategies involving the depletion of 
inflammatory cell types (i.e. alveolar macrophages or neutrophils) not only have shown 
conflicting experimental results [87–90], but would translate poorly into clinical practice 
due to issues of safety and feasibility, given the undeniable importance of innate immunity 
in host defense and tissue repair.  
The rather intuitive approach of targeting individual cytokines or chemokines to down-
modulate the inflammatory response has also proven ineffective in both experimental and 
clinical studies. The work of Nakamura et al. showed that mice lacking the expression of 
the cytokine IL-6 had similar physiological impairments than wild type mice, following 
exposure to three different models of ALI [91]. A more recent study by Markovic et al. 
demonstrated that, while solutions containing lung-derived inflammatory mediators caused 
liver endothelial cell dysfunction, the neutralization of IL-6 or TNF-α found in such 
solutions was ineffective in rescuing the alterations in endothelial cells [64]. Clinically, an 
antibody against TNF-α or administration of IL-1β Receptor Antagonist have been tested 
for the treatment of severe sepsis, a known cause of ALI (Fig. 1.1), but failed at reducing 
mortality in this patient population [92, 93].  
Attempts at modulating the inflammatory response associated with ALI have also been 
made with the clinical evaluation of corticosteroids. As emerges from a recent meta-
analysis of several clinical studies, corticosteroid therapy in ALI showed no effect on long 
term mortality, and even appeared to significantly harm patients with influenza-related 
lung injury [94]. 
Taken together, this evidence underscores the necessity for further understanding of the 
inflammatory response and the need for new therapeutic strategies. In this regard, we 
believe that lung surfactant and the protease matrix metalloproteinase-3 might be such 
potential strategies. An overview dedicated to their role in inflammation and ALI is given 
in the following sections of this introductory chapter.  
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1.6. The pulmonary surfactant system 
Being an important contributor in the pathogenesis of ALI and a marker of disease 
progression, the pulmonary surfactant system has been the focus of intense in vitro, in vivo, 
and clinical research over the last five decades. 
As mentioned earlier, the biophysical role of pulmonary surfactant is to reduce the surface 
tension at the air-liquid interface, thereby ensuring optimal lung compliance [1]. The 
decrease in pulmonary compliance typical of ALI generally results from the impairment of 
surfactant activity [95].  
In addition to its surface tension reducing properties, lung surfactant has also an important 
role in immune modulation and host defense within the alveolar environment [9]. 
Interestingly, less is known about this function in the context of ALI. 
1.6.1. Surfactant composition 
The composition of surfactant is conserved across mammalian species and consists of 
approximately 90% lipids, primarily phospholipids, and 10% surfactant associated proteins 
[8]. The most abundant phospholipid component is phosphatidylcholine (PC), half of 
which is dipalmitoylphosphatidycholine (DPPC), a disaturated species important for 
achieving low surface tension values at the end of expiration [8]. 
The protein components include four surfactant associated proteins: surfactant protein-A 
(SP-A), surfactant protein-B (SP-B), surfactant protein-C (SP-C) and surfactant protein-D 
(SP-D) [96, 97]. The large, hydrophilic SP-A and SP-D proteins are members of the 
collectin family and participate in the innate immune response [98]. SP-B and SP-C are 
small, highly hydrophobic proteins very intimately associated with the lipids. SP-B and 
SP-C proteins are important for promoting the formation of the surface film and supporting 
its biophysical function [99]. 
 
 
21 
 
1.6.2. Surfactant metabolism 
All of the surfactant components are synthesized and secreted by the alveolar type II cells 
(Fig. 1.2) [100]. Surfactant is exocytosed into the alveolar space from storage organelles, 
the lamellar bodies, found within type II cells [101]. SP-B and SP-C are assembled and 
secreted together with the lipids, while synthesis and release of SP-A and SP-D is mainly 
independent from lipid metabolism [102, 103]. There is some evidence, however, that SP-
A may be secreted in association with the lamellar bodies as well (Fig. 1.2) [104, 105].  
 
Figure 1.2: Surfactant metabolism. Surfactant is a protein-lipid mixture synthesized by 
type II alveolar cells, stored in lamellar bodies and secreted into the liquid hypophase. 
Tubular myelin is then generated and adsorption of phospholipids to the interface creates 
a surface film enriched in DPPC. Breathing motion causes formation of small vesicles, 
which are up-taken by type II cells or cleared by alveolar macrophages (AM). LA, large 
aggregates; SA, small aggregates.  
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Following secretion, the surfactant from the lamellar bodies undergoes reorganization into 
tubular myelin, a lattice-like structure that is then adsorbed rapidly to the air-liquid 
interface where it forms a monolayer film [102]. Upon ventilation, the changes in the 
alveolar surface area favor the conversion of surfactant into small vesicles with poor 
biophysical activity. Pulmonary surfactant can be collected through lung lavage, and the 
vesicular forms can be subsequently isolated via differential centrifugation of lung lavage 
samples. The process leads to the separation of a larger, heavier sub-fraction named large 
aggregates (LA) and small, lighter vesicles called small aggregates (SA) [106, 107]. The 
LA component consists of structures from the lamellar bodies, tubular myelin, surfactant 
proteins SP-A, SP-B, and SP-C and has excellent surface tension reducing properties [108, 
109]. As mentioned, changes in the pulmonary surface area determine the conversion of 
large aggregates into SA, the latter being the biophysically inactive sub-fraction with lower 
content of surfactant-associated proteins [108]. Lastly, clearance of inactive surfactant 
occurs via reuptake and recycling from alveolar type II cells, or through phagocytosis and 
degradation within alveolar macrophages (Fig. 1.2) [102, 103].  
1.6.3. Surfactant function 
As previously mentioned, the biophysical function of surfactant consists in lowering the 
surface tension at the air-liquid interface [8]. Without surfactant, the water molecules at the 
very surface of the liquid hypophase would experience a net inward force, attracting them 
to the bulk of the liquid. In this situation, as the surface area decreases (ie. during 
exhalation), the high surface tension would resist lung expansion and a relatively high 
pressure would be necessary to re-open the lung. This would decrease alveolar stability 
and promote alveolar collapse. The presence of the surfactant film at the air-liquid interface 
assures a reduction of the surface tension to values near zero mN/m, with DPPC being the 
primary component contributing to alveoli stabilization at low lung volume [110, 111]. 
Importantly, the hydrophobic proteins SP-B and SP-C also participate in this process by 
promoting lipid adsorption at the interface and facilitating the re-spreading of surfactant 
during inspiration (corresponding to an expansion in surface area) [22, 99, 112]. The roles 
of SP-B and SP-C in surfactant function become particularly evident when analyzing the 
phenotype of mice in which the expression of either protein had been knocked out. Mice 
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lacking SP-B are not viable and die shortly after birth due to respiratory distress. Lack of 
SP-B impairs the generation of lamellar bodies and tubular myelin, highlighting the 
essential role of this surfactant protein in lipid organization [99, 113]. Conversely, the 
phenotype of mice with SP-C deficiency is not as dramatically altered, with pulmonary 
surfactant from these mice exhibiting minor biophysical changes at low lung volume, 
thereby supporting the importance of SP-C in film stabilization at the end of expiration 
[114]. 
The collectin SP-A contributes as well to the biophysical function of surfactant. SP-A aids 
in lipid adsorption and in the structural organization of the surfactant film undergoing 
cycles of compression and expansion [115, 116]. This surfactant-associated protein is also 
important for limiting the impairment in biophysical function consequent to intra-
pulmonary leakage of serum albumin [117]. 
SP-A, however, together with SP-D, is primarily involved in the immuno-modulatory 
functions of surfactant [9]. SP-A and SP-D can opsonise viruses and bacteria and promote 
their clearance via phagocytosis by inflammatory cells within the lung; in line with this 
evidence, mice genetically modified to lack SP-A or SP-D expression succumb more easily 
to bacterial infection [118–120]. In addition to such activities, SP-A can influence the 
secretion of inflammatory mediators by peripheral immune cells and alveolar 
macrophages, the production of reactive oxygen species, and can inhibit lymphocyte 
proliferation [76, 121]. 
Furthermore, SP-B, SP-C, and some of the surfactant phospholipids have been shown to 
contribute to the immuno-modulatory properties of surfactant, as they can regulate the 
inflammatory response elicited by a variety of stimuli both in vitro and in vivo [122–125]. 
Of note, the aforementioned SP-C deficient mice appear to mount a more robust 
inflammatory response, and to be more severely impacted by bacterial or viral infections 
than wild type mice, thereby unraveling the anti-microbial and anti-inflammatory 
properties of SP-C [126, 127]. 
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Overall, both the immuno-modulatory and biophysical properties of surfactant are essential 
for lung homeostasis, and the importance of a functional surfactant system is particularly 
relevant in the pathogenesis of ALI. 
1.6.4. Surfactant alterations in ALI 
Surfactant impairment can be considered one of the hallmarks of ALI. Analyses of lung 
lavage samples from numerous animal models and patients with ALI have shown changes 
in phospholipid composition with decreased DPPC, decreased levels of SP-A, SP-B, SP-
C, and higher conversion of large aggregates into functionally inactive SA (Fig 1.3) [95, 
128–131]. These alterations are likely dependent on a number of factors.  
Firstly, injury to the alveolar type II cells during ALI can hinder any of the steps in 
surfactant metabolism, affecting phospholipid species, surfactant protein levels, and 
availability of functional large aggregates [128, 132].  
Secondly, mechanical ventilation and the broad milieu of inflammatory mediators within 
the alveolar space contribute to the aforementioned alterations. Specifically, it has been 
observed that the changes in alveolar surface area associated with MV increase the 
conversion of LA into SA pools, and this is particularly relevant when ventilation with high 
tidal volumes is utilized [133–135]. The inflammatory mediators in the injured lung can 
degrade the different surfactant components via phospholipases and proteases released by 
immune cells or invading pathogens. For example, enzymes secreted by Pseudomonas 
Aeruginosa have been shown to degrade surfactant lipids as well as SP-A, SP-B and SP-
D, and increase LA to SA conversion in vitro [136–138].  
Lastly, leakage of serum proteins into the lung due to the more permeable alveolo-capillary 
barrier considerably contributes to surfactant alterations in ALI. Albumin, hemoglobin, and 
the accumulation of fibrin rich material favored by reduced fibrinolytic activity largely 
contribute to surface film impairment (Fig. 1.3) [48, 139]. 
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Figure 1.3: Surfactant alterations in ALI. The figure represents the increased conversion 
of LA into SA, dysfunction of type 2 cells, and inhibition of surfactant due to leakage of 
serum proteins. 
 
The functional implications of surfactant alterations in ALI result in higher surface tension, 
lower lung compliance, hypoxemia, and possible loss of surfactant immuno-modulatory 
and host defense properties. It is important to note that the alterations of surfactant are not 
just the consequence of the disease process, but they also directly contribute to injury 
progression. Surfactant changes occur, in fact, relatively early in ALI pathophysiology, as 
demonstrated by the work of Maruscak and colleagues [10]. In this study, surfactant 
dysfunction was assessed in rats exposed to one hour or two hours of high Vt MV. Changes 
such as increase in SA content, decrease in percent LA, and impaired ability of isolated 
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surfactant to reduce surface tension occurred within the first hour of injurious MV, in the 
early stages of injury and before any physiological dysfunction (such as hypoxemia or low 
compliance) was detectable [10]. This experimental evidence is also supported by clinical 
observations, in which lung lavage collected from ALI patients within 24 hours from 
intubation showed already significantly lower PC and DPPC levels, lower SP-A/SP-B/SP-
C, and higher minimum surface tension compared to healthy, spontaneously breathing 
controls [131].  
Overall, this evidence suggests that alterations and impairment of the endogenous 
surfactant system contributes to lung dysfunction in ALI resulting in decreased compliance 
and hypoxemia. These findings constitute the main rationale for exogenous surfactant 
administration as a potential treatment of this disorder. 
1.6.5. Exogenous surfactant treatment in ALI 
The concept of exogenous surfactant treatment in ALI stems from the necessity to 
overcome endogenous surfactant alterations impairing the function of the lung. Throughout 
the years, different surfactant preparations have been investigated in both experimental and 
clinical settings. Such preparations differ in terms of source of surfactant (natural versus 
synthetic, or different animal origin) and content of surfactant associated proteins; 
however, none of them contains SP-A or SP-D, for reasons related to the purification 
process of natural surfactants or commercial considerations. Natural surfactant 
preparations are derived from either porcine (Curosurf, HL-10) or bovine (bLES, 
Alveofact, Infasurf, Survanta) sources, and contain natural lipids as well as SP-B and SP-
C, while synthetic surfactants are protein-free (Exosurf and ALEC) or contain recombinant 
SP-C protein or a SP-B like peptide (Venticute and KL4, respectively) [40].  
Extensive animal studies have been performed to evaluate the efficacy of exogenous 
surfactant administration in models of ALI, leading to exciting results with improvements 
in oxygenation and compliance in the treated animals [11, 140–142]. In line with the 
experimental findings, initial case reports and small clinical trials evidenced a beneficial 
effect of exogenous surfactant on oxygenation in patients with ALI [40, 143]. The 
subsequent controlled, multi-center, prospective, randomized trials focused on clinical 
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outcomes such as ventilator-free days (VFD) and mortality. Even though surfactant 
treatment proved to be safe and led to acute improvements in oxygenation, these trials 
showed no change in VFD or mortality in the surfactant treated patients compared to 
patients exposed to standard care [40, 144–146].  
The factors that may have affected the outcomes of exogenous surfactant treatment are 
multiple, and include: the dose and method of surfactant delivery, the type of surfactant 
preparation used, and the severity of the underlying injury.  
An additional factor that may have influenced the efficacy of surfactant treatment is the 
timing of administration [40]. It is in fact possible that exogenous surfactant was 
administered too late into ALI progression, when systemic inflammation and distal organ 
failure may have already developed (Fig. 1.1); therefore, administration at earlier time 
points may prove more beneficial.  
Lastly, it is important to note that improvements in oxygenation following surfactant 
treatment did not correlate with a mortality benefit. Remarkably, the only approach (low 
Vt MV) achieving a decrease in mortality was associated with lower systemic 
inflammation [12, 37]. It would be, therefore, of interest to investigate the relationship 
between exogenous surfactant treatment and inflammation during ALI. In this respect, 
recent data from our lab suggests that elevated endogenous surfactant pool sizes can 
mitigate the inflammation associated with ALI, in mice exposed to injurious MV only or 
to a combination of lipopolysaccharide instillation and MV [147, 148]. The intriguing 
question of whether exogenous surfactant treatment can mirror those findings and have an 
impact on the inflammatory response during ALI will be addressed in chapter 2 of this 
thesis. 
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1.7. Overview on matrix metalloproteinases (MMPs) 
As previously discussed, mitigation of the inflammation in ALI is central to hindering 
disease progression. As mediators of inflammation and potential therapeutic targets, matrix 
metalloproteinases are of particular interest, with one of these proteases, namely MMP-3, 
being the experimental variable under investigation in this thesis (chapters 3 and 4). 
The matrix metalloproteinase family consists of 25 zinc-dependent endopeptidases 
produced by immune cells, epithelial cells, and fibroblasts, and characterized by similar 
structural features [17, 149–151]. The initial view on the function of MMPs was that of 
proteases exclusively dedicated to matrix remodeling. A growing body of research, 
however, has now shown that a large part of the MMP substrates are non-matrix molecules, 
and that MMPs play important roles in many different physiologic and pathologic 
processes. The functions of MMPs span, in fact, from organogenesis to wound repair, 
fibrosis, and, above all, inflammation [152–154]. Importantly, and contrary to the original 
view, advancements in the biology of MMPs suggest distinct and non-overlapping 
functions for these proteases in vivo. The original misconception mainly originated from 
in vitro observations, where different MMPs were shown to cleave the same substrates. 
The case against such redundant/overlapping roles for MMPs is supported by differences 
in MMPs cell expression and their diverse pericellular localization, which affects substrate 
availability in vivo. Additionally, it should be noted that there are emerging non-enzymatic 
activities for several MMPs that further undermine the concept of functional overlap for 
these enzymes [155–157].  
Due to the potential effects of MMPs on multiple molecules and biological events, their 
activity undergoes different levels of regulation. For instance, MMPs are released as latent 
pro-enzymes and, once activated, their activity is limited by alpha 2 macroglobulin or 
specific endogenous inhibitors such as the tissue inhibitors of metalloproteinases (TIMPs). 
MMPs are also regulated at the transcriptional level, with their expression being typically 
low in healthy tissue, and up-regulated in pathological conditions such as infection, injury 
and, most importantly, inflammation [17, 158].  
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Elevated levels and activity of various MMPs have been observed in inflammatory 
conditions such as atherosclerosis, asthma, sepsis, and acute lung injury [159–162]. Far 
from being simple by-standers, these enzymes actively participate in the inflammatory 
process, through regulation of the activation and availability of several cytokines and 
chemokines [152].  
Several clinical studies have in fact observed elevated levels of some MMPs, including 
MMP-1, -2, -3, -8, and -9, in lavage fluids of patients with ALI [163–165]. Importantly, 
one of this studies showed that MMP-3 levels correlated with disease severity, incidence 
of multi-organ failure, and mortality [163]. In light of this evidence, it is of interest to 
specifically investigate MMP-3 contribution to the pathophysiology of ALI. 
 
1.8. Matrix metalloproteinase-3 (MMP-3) 
1.8.1. Characteristics of MMP-3 
Matrix metalloproteinase-3, also called stromelysin-1, is an extracellular, secreted MMP 
whose levels are low in healthy tissue, but increase following injury or inflammation. 
Within the lung, MMP-3 is expressed by epithelial cells, alveolar macrophages, and 
fibroblasts [151, 166]. 
MMP-3 structure consists of a pro-domain, a catalytic domain, a hinge region and a 
hemopexin domain. The pro-domain contains a conserved cysteine residue, whose thiol 
group interacts with a zinc (Zn2+) ion coordinated by the catalytic domain [167, 168]. The 
interaction between the thiol group of the conserved cysteine and the Zn2+ maintains MMP-
3 in a zymogen state, and activation occurs through the proteolytic removal of the pro-
domain or the disruption of the Zn2+-cysteine interaction via a chaotropic agent [169]. As 
mentioned, MMP-3 also has a flexible hinge region, and a C-terminal hemopexin-like 
domain that is important in substrate recognition [168].  
Since its first description in the ‘70s and isolation in the mid ‘80s, the knowledge about 
MMP-3 in physiology and disease has substantially increased, and new emerging roles for 
this protease are still being discovered. Like other members of this family, MMP-3 has 
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multiple and diverse substrates. It can degrade components of the extracellular matrix 
(ECM), such as cross-linked fibrin, fibrinogen, fibronectin, elastin, laminin, collagens and 
proteoglycans [162, 170–172]. Consistent with a role in ECM remodeling, MMP-3 
participates in wound healing where it regulates wound contraction and speed of wound 
closure [173, 174]. Beside the ECM, MMP-3 has also been shown to cleave non-matrix 
substrates. For example, it degrades protease inhibitors, and takes part in the proteolytic 
activation of other MMPs such as MMP-1, -8 and MMP-9 [162, 175–178].   
Cell-to-cell contacts are also affected by MMP-3 through cleavage of E-cadherin, protein 
situated at the junctions between epithelial cells and important for maintenance of the 
integrity of the alveolo-capillary barrier [151, 170]. While shedding of E-cadherin could 
contribute to the development of lung injury, MMP-3 role in the regulation of inflammation 
is of greater importance in the pathogenesis of ALI. 
1.8.2. MMP-3 in the inflammatory process  
MMP-3 has a widespread effect on the inflammatory signaling. MMP-3 can proteolytically 
activate the latent forms of TGF-β and TNF-α, and is responsible for both activation and 
subsequent degradation of IL-1β [17, 179, 180]. Moreover, MMP-3 cleaves several CC 
and CXC chemokines generating receptor antagonists (RANTES, MCP-1, MCP-2, MCP-
3, and MCP-4), leading to inactivation (SDF-1), or generating chemotactic gradients [152]. 
It has in fact been shown that MMP-3 is essential to the generation of an unknown 
macrophage chemo-attractant in a model of herniated disc resorption and may participate, 
among other MMPs, to the activation of NAP-2, a potent neutrophils chemo-attractant 
[181, 182]. This considerable involvement in the inflammatory response is possibly the 
reason for a role of MMP-3 in various inflammatory diseases, such as atherosclerosis, 
endometriosis, sepsis and, importantly, ALI.  
1.8.3. MMP-3 in ALI 
The involvement of MMP-3 in ALI is suggested not only by the aforementioned clinical 
evidence, but also by some experimental data. These studies have utilized Mmp3 wild type 
(Mmp3+/+) and knock out mice (Mmp3-/-) to specifically assess the role of such protease in 
injury development. In the study by Warner et al, Mmp3+/+ and Mmp3-/- mice were exposed 
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to a model of acute alveolitis; subsequently, histological analysis and measurements of 
protein content and cellularity in lavage were performed [183]. The authors observed 
reduced protein levels and neutrophils number in the lavage of injured Mmp3-/- mice 
compared to Mmp3+/+ controls, thereby suggesting a role for MMP-3 in the development 
of injury [183]. These findings are supported by a later study in which lung injury was 
induced through the intra-tracheal instillation of the chemokine CXCL2/MIP-2 [184]. In 
this model as well, Mmp3-/- mice appeared to develop milder injury, indicating a role for 
MMP-3 in lung permeability and neutrophil recruitment following an inflammatory injury 
[184]. 
Even though these experimental findings are of great interest, they are characterized by 
some important limitations. First, these models of lung injury lack clinical relevance, since 
the primary insults utilized to initiate ALI do not closely resemble common ALI etiologies 
[2]. Second, both models are essentially based on neutrophilic infiltration, while models 
reflecting more of the hallmarks of ALI (see section 1.9) would be desirable. Lastly, in-
depth analyses of pulmonary inflammation and ALI outcomes such as surfactant alterations 
and changes in lung mechanics have not yet been performed and are necessary to the 
understanding of MMP-3 role in such complex disease.   
1.8.4. Study tool: Mmp3 knock-out mouse 
As pointed out previously, the use of genetically modified mice lacking the expression of 
Mmp3 is a powerful tool to investigate, specifically, MMP-3 contribution to injury and 
inflammation.  
The first MMP-knock out to be developed, Mmp3-/- mice are viable, fertile, and have 
normal lung structure and function under unchallenged conditions (chapter 4 of this thesis 
and [151]). Following injury, however, Mmp3-/- mice present different phenotype from 
wild type mice, and examples of the inflammatory phenotype of Mmp3-/- mice in several 
injury models are listed in Table 1.2.  
Overall, the Mmp3-/- mouse appears to be an adequate and reliable tool to expand the 
understanding of MMP-3 role in the pathogenesis of ALI and, for such reasons, has been 
the model of choice in our studies (chapters 3 and 4). 
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Mouse Inflammatory phenotypes Ref. 
Mmp3-/- 
Reduced neutrophils count in immune complex induced lung 
injury 
[183] 
Decreased pulmonary fibrosis following bleomycin instillation [151] 
Increased susceptibility to collagen induced arthritis [185] 
Inhibited macrophage infiltration in an in vitro model of 
herniated disc resorption 
[181] 
Impaired contact hypersensitivity and T cell response to 
intestinal bacterial infection 
[186] 
Table 1.2: Examples of inflammatory phenotypes described in Mmp3-/- mice. 
 
1.9. Animal models of ALI 
To effectively interfere with lung injury development and progression, the use of animal 
models reproducing the biological and physiological characteristics of ALI is essential. 
Animal models allow the use of specific research tools, for example the utilization of 
genetically modified animals, to elucidate specific mechanistic pathways involved in the 
disease, which would be otherwise impossible to directly study in human patients. A sole 
animal model, however, cannot resemble all of the disease features due to the variety of 
initiating insults and the complex pathophysiology of ALI. The optimal solution for the 
study of this disease resides, then, in the use of different experimental models, exposed to 
different initiating lung insults, and resembling the multiple hit paradigm of ALI 
development (Fig. 1.1). Most importantly, any animal model utilized should mirror the 
hallmarks of ALI (described below) to adequately reflect the disease pathophysiology. 
1.9.1. Hallmarks of ALI in animal models 
The hallmarks of ALI, ideally addressed by experimental models to mimic human lung 
injury, stem from the definition and clinical evidence for such disorder. These hallmarks 
include: i) acute onset, ii) physiological dysfunction, iii) pulmonary (and systemic) 
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inflammation, iv) increased pulmonary permeability, and v) histological evidence of lung 
injury [187, 188]. 
Specifically, in valid models of ALI lung injury should develop shortly after the exposure 
to the insults (acute onset), and lead to the manifestation of physiological dysfunction. The 
latter implies the presence of pulmonary surfactant alterations, impaired gas exchange, and 
changes in lung mechanics [2]. Analyses of pulmonary surfactant can be readily performed 
on isolated samples of lung lavage undergoing differential centrifugation. Following 
isolation of total surfactant, large, and small aggregates, the abundance of each sub-fraction 
can be determined through well-established biochemical assays [189, 190]. Moreover, 
surfactant biophysical properties can be evaluated in vitro, by monitoring the minimum 
surface tension achieved by LA samples exposed to repeated cycles of compression and 
expansion via captive bubble surfactometer [191] (chapter 2) or constrained sessile drop 
surfactometer [192] (chapter 4). With the exception of surfactant analyses, assessment of 
physiological dysfunction can pose a technical challenge, especially in mice, and may not 
be always feasible. Measurements of oxygenation often require the use of invasive arterial 
catheters, and are limited by a small total blood volume. Physiological parameters are also 
hard to measure in spontaneously breathing animals, but can be assessed in mechanically 
ventilated mice. MV allows in vivo and ex vivo monitoring of changes to peak pressure 
and/or lung compliance [193]; furthermore, as previously mentioned, MV augments the 
pulmonary inflammation associated with ALI, and contributes to the systemic 
inflammatory response [13, 58].  
Pulmonary inflammation, a definite hallmark of ALI, comprises increased lavage 
inflammatory mediators and neutrophil numbers, and can be effectively measured in lung 
lavage samples through commercially available assays and analysis of total and differential 
cell counts. Lung lavage samples can also be utilized to evaluate increases in total protein 
content, thereby illustrating, with some limitations, increases in pulmonary permeability, 
another characterizing aspect of lung injury [188]. 
Lastly, a good animal model of ALI should provide histological evidence of lung injury, 
since histological analyses can give both qualitative and quantitative information on the 
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extent and uniformity of the injury, cellularity, sites of edema accumulation, and gross 
structural abnormalities [188].  
In conclusion, it should be noted that most animal models of ALI present at least a few of 
the hallmarks described above. While a description of all the models available for the study 
of this disease goes beyond the scope of this chapter, the main characteristics of the lung 
injury models relevant to this thesis are described in the following paragraphs. 
1.9.2. Hydrochloric acid-induced lung injury 
Gastric acid aspiration refers to the unintentional inhalation of the gastric content, and is 
one of the direct pulmonary insults predisposing the lung to ALI (Fig. 1.1). It accounts for 
about 30% of all the deaths due to anesthesia, and can also occur in subjects experiencing 
drug overdose or seizures [194]. Even though gastric aspiration exposes the lung to both 
particulate matter and acidic juices from the stomach, this injury has been widely modelled 
through the intra-tracheal instillation of hydrochloric acid (HCl) solutions with low pH [58, 
195, 196].  
Animal models of acid-induced ALI are characterized by acute pulmonary changes, 
detectable as early as four hours post HCl instillation (chapters 2 and 3) [58]. Lung injury 
results from the chemical burn of the pulmonary parenchyma, subsequently leading to 
elevated lavage concentrations of inflammatory cytokines and chemokines involved in 
neutrophils recruitment. Acid-induced ALI, in fact, appears to be neutrophil dependent, as 
demonstrated by marked pulmonary infiltrates and, conversely, by the development of 
milder injury when neutrophils accumulation in the lung is inhibited or decreased [67, 197, 
198]. While it is not entirely clear how acid injury activates the immune system, some 
recent study suggests that the Toll-like receptor 4 (TLR4) pathway may be involved [199]. 
Being a direct lung insult, the alveolar epithelium is especially affected, with loss of 
epithelial cells, alterations of the alveolo-capillary barrier and consequent surfactant 
impairment [187]. Additional signs of physiological dysfunction, such as increased peak 
pressure and decreased compliance, have also been observed in this model of ALI [58, 
196]. 
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1.9.3. Lipopolysaccharide-induced lung injury 
Bacterial pneumonia is one of the most common causes of ALI [2]. This injury has been 
extensively reproduced in experimental models through the intra-nasal or intra-tracheal 
administration of bacteria or lipopolysaccharide (LPS), an immunogenic molecule found 
in the outer membrane of Gram negative bacteria. While administration of live bacteria 
constitutes a valid alternative in modeling pneumonia, LPS has the advantage of being easy 
to prepare and administer, and ensures a good degree of reproducibility [187]. 
LPS instilled intra-tracheally directly affects both the alveolar macrophages and epithelium 
by binding to its receptor, TLR4, on these cells and activating intracellular pathways 
leading to synthesis and release of multiple cytokines and chemokines [200]. LPS-induced 
lung injury then develops presenting most of the hallmarks of ALI described above, as 
highlighted by the analyses of pulmonary permeability and inflammation, physiological 
dysfunction and histological damage described throughout chapters 3 and 4 of this thesis. 
For such reasons, LPS-induced ALI is a very useful and informative model in the study of 
this disorder. 
1.9.4. Ventilation associated lung injury and ex vivo ventilation 
As previously mentioned, mechanical ventilation is the main supportive treatment in ALI 
necessary to improve oxygenation, and a crucial component of ALI pathophysiology as a 
potential secondary insult. Experimentally, the role of MV in ALI has been investigated in 
isolation, overstretching the lung by applying high tidal volume MV to healthy lungs. This 
injury model is referred to as ventilator-induced lung injury (VILI) and allows the study of 
specific alterations in pulmonary function, inflammation and cell signaling resulting from 
excessive mechanical stretch and strain implemented on otherwise normal lungs [201, 
202].  
While VILI is an experimental tool of great analytical value, in a clinical setting ventilation 
is utilized to support lung function, which is already impaired due to a pre-existing injury. 
The study of ventilation in clinically relevant, in vivo or ex vivo models is therefore 
performed by implementing MV on lungs that have been pre-exposed to a clinically 
significant insult, such as aspiration or pneumonia. Such models of ventilation-associated 
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lung injury (VALI) directly examine the role of MV as a secondary insult in propagating 
lung injury and in contributing to the development of systemic inflammation and associated 
distal organ failure [14, 52, 58]. Overall, models of VILI and VALI have been essential in 
demonstrating that MV can lead to damage via over-distention and repeated 
opening/closing of alveolar units, and have convincingly pointed out that the extent of the 
injury is proportional to the degree of mechanical stress applied to the lung.  
The mechanisms through which ventilation can cause and exacerbate injury are barotrauma 
(gross lung injury due to excessive airway pressure), volutrauma (excessive volume 
applied to the lungs) and, particularly relevant for this thesis, biotrauma [55, 203]. The 
concept of biotrauma refers to the release of biologically active mediators from lungs 
exposed to injurious modalities of MV, mediators that can potentially translocate into the 
circulation and damage distal organs [56]. Evidence for the biotrauma hypothesis stems 
from a vast body of in vitro, in vivo and ex vivo research. Numerous studies have in fact 
shown release of inflammatory molecules and changes in gene expression in alveolar 
epithelial cells and macrophages exposed to cycles of mechanical stretch [56, 204, 205]. 
These in vitro findings have been mirrored by in vivo experimental observations, in which 
high pressure or high volume ventilation caused elevated pulmonary and systemic levels 
of cytokines and chemokines, often in combination with changes in peripheral organs [14, 
58, 79]. Notably, Imai and colleagues have demonstrated that, in a model of acid-induced 
ALI followed by injurious MV, lung derived mediators in the systemic circulation led to 
increased apoptosis in the kidneys and small intestine of the experimental animals, thereby 
strongly supporting the biotrauma concept [61].  
A particularly useful tool to study biotrauma and the effects of MV on the lung in isolation 
is a system for ex vivo ventilation, namely the isolated and perfused mouse lung (IPML) 
set up [59]. The IPML set up allows for ex vivo MV of mouse lungs and simultaneous re-
circulation of a cell free solution through the pulmonary blood vessels. One of the main 
advantages of this system resides in the possibility to collect and analyze inflammatory 
mediators specifically released from the lung into the circulation throughout MV [59, 86]. 
Importantly, the IPML system allows the monitoring of potential changes in the levels of 
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these circulating, lung-derived mediators resulting from lung specific treatments, as 
illustrated in chapter 2 of this thesis. 
1.9.4.1. Measurements of lung mechanics in small rodents 
An undoubtable advantage associated with the use of MV in small rodents is the possibility 
to evaluate lung mechanics. Measurement of physiological parameters in spontaneously 
breathing animals is, in fact, quite difficult and usually not very precise [206]. For example, 
whole-body plethysmography can be used in unrestrained, conscious animals; this 
technique, however, provides only general information about the pattern of ventilation, and 
it can generate errors and artifacts. On the other hand, MV is a more invasive procedure, 
requiring restrain, surgery and anesthesia management for in vivo models, but providing 
the valuable advantage of reliable, reproducible, and accurate measurements [207]. While 
in vivo MV was not utilized in this thesis work, models of ex vivo ventilation and ex vivo 
measurements of lung function were applied to terminally sacrificed mice [59, 208, 209]. 
These strategies allowed the monitoring of peak inspiratory pressure changes throughout 
MV (chapter 2) and the specific assessment of several parameters, such as: compliance, 
resistance, and elastance for the whole respiratory system; quasi-static compliance and 
elastance; central airway resistance (RN); tissue resistance or tissue damping (G); and tissue 
elastance (H) (chapter 4); thereby providing complete and novel information on 
physiological dysfunction in our models of ALI.  
1.10. Summary and overall objective 
The lung is the organ responsible for gas exchange, a vital function that is severely impaired 
during acute lung injury. This life threatening condition can be initiated by multiple and 
diverse insults to the lung, resulting in profound alterations of the alveolar 
microenvironment. Among such alterations, the impairment of the surfactant system and 
the development of an extensive pulmonary inflammatory response are key events in the 
progression of the disease. Despite extensive research, the highly complex 
pathophysiology of ALI has hindered the development of an effective therapeutic treatment 
capable of reducing the high mortality associated with this disorder. Further investigation 
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is, therefore, necessary to improve applicable interventions and identify key mediators of 
lung injury that could serve as potential therapeutic targets.  
The overarching hypothesis of this thesis work is that interventions targeting the 
inflammatory response associated with ALI can improve outcomes. The overall objective 
is then to expand our understanding of the ALI pathophysiology, in order to better interfere 
with disease progression and provide potential future alternatives in the treatment of ALI.  
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2.1. Introduction  
Pulmonary surfactant is a mixture of phospholipids, surfactant-associated proteins and 
neutral lipids which has an important role in the lung in both host defence mechanisms 
such as modulating pulmonary inflammation and in stabilizing the alveoli by reducing 
surface tension [1, 2]. Both biophysical and immuno-modulatory properties of 
endogenous surfactant are essential for normal lung function. Importantly, both properties 
are severely impaired during the course of acute lung injury (ALI) [3, 4]. 
ALI is a life threatening condition characterized by bilateral pulmonary infiltrates on 
chest radiograph, alveolar edema and hypoxemia [5]. Mortality is approximately 30-40%, 
with the main cause of death resulting from multiple organ failure (MOF) rather than 
respiratory failure. The former is thought to develop in large part due to the release of 
inflammatory mediators from the lung into the circulation thereby contributing to 
excessive systemic inflammation. This, in turn, causes MOF and death [6-8]. 
The main supportive therapy required to maintain adequate oxygenation for patients with 
ALI is mechanical ventilation (MV). Unfortunately, this intervention is also an important 
component of the complex pathophysiology of ALI, since it can increase pulmonary 
inflammation and contribute to the development of the associated systemic inflammation 
leading to MOF [9-13]. A pharmacological therapy capable of mitigating the specific 
inflammatory effects of MV thereby reducing the contribution of the lung to the systemic 
inflammation is needed. Based on the known properties of surfactant within the lung, the 
current study investigated on such potential therapy namely exogenous surfactant 
administration.  
Exogenous surfactant has been investigated as a possible therapy for ALI in many 
experimental and clinical studies [14-17]. Traditionally surfactant treatment has been 
administered to improve the biophysical function of this material within the lung. 
Although extensive research has shown improvements in physiological and biophysical 
outcomes following surfactant treatment, there was no effect on mortality [18]. 
Contrasting this extensively investigated approach, only a limited number of studies have 
evaluated surfactant with the aim to down-regulate the systemic inflammation associated 
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with ALI and MV. Previous studies in our laboratory demonstrated that elevated 
endogenous surfactant pool sizes prior to MV attenuated the development of pulmonary 
and systemic inflammation in animal models where injurious MV was applied to normal 
lungs [19] or conventional ventilation was applied to lungs with a pre-existing injury 
(lipopolysaccharide-induced ALI) [20]. Whether exogenous surfactant can mirror these 
observations obtained with elevated endogenous surfactant is not known. It was therefore 
hypothesized that administration of exogenous surfactant prior to MV would reduce the 
systemic inflammation associated with lung injury. 
To test this hypothesis, two separate mouse models were utilized: i) a model of 
mechanical ventilation in animals with otherwise normal lungs and ii) a model of acid-
induced lung injury followed by MV. For both experiments, exogenous surfactant was 
administered prior to MV, and the ventilation was performed ex vivo using an isolated 
and perfused mouse lung (IPML) setup. The inflammatory mediators released by the 
lungs into the circulation were collected (via left ventricle) in perfusate and re-circulated 
(via pulmonary artery) throughout MV. This ex vivo circulatory system in the IPML setup 
allowed us to isolate the contribution of mechanically ventilated lungs to the systemic 
system, with perfusate representing a surrogate of systemic inflammation.  
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2.2. Materials and methods 
2.2.1. Experimental design and ethics statement 
A total of 36 male 129X1/SVJ mice (Jackson Laboratories, Bar Harbor, Me., USA) were 
utilized for two separate animal experiments. All procedures were approved by the 
Animal Use Subcommittee at the University of Western Ontario (Permit Number: 2010-
272) and, whenever necessary, adequate anesthetic regimen was used to minimize 
suffering. For both experiments, mice were allowed to acclimatize for a minimum period 
of 72 hours in an animal facility, during which time they were allowed free access to 
water and standard chow.  
In order to test our hypothesis of an anti-inflammatory role of surfactant toward the 
effects of MV, administration of exogenous surfactant was performed in two separate 
models of lung injury: experiment 1 involved the use of MV only and experiment 2 
involved the use of intra-tracheal (i.t.) instillation of hydrochloric acid (HCl) followed by 
conventional MV.  
In experiment 1, mice were anaesthetized and subsequently randomized to either 
exogenous surfactant administration or no treatment. After the completion of the i.t. 
surfactant instillation, mice were connected to the IPML setup and exposed immediately 
following re-perfusion to MV with a tidal volume (Vt) of 20ml/kg, a positive end 
expiratory pressure (PEEP) of 3 cmH2O, and a respiratory rate (RR) of 30 breaths/min. 
This resulted in the randomization of a total of 12 mice to one of the two experimental 
conditions: i) No Treatment group or ii) bLES group. 
In experiment 2, a total of 24 male 129X1/SVJ mice were anaesthetized and then 
randomized to receive an intra-tracheal instillation of HCl or air. Four hours after the 
development of acid-induced lung injury, mice were randomized to receive an intra-
tracheal exogenous surfactant administration (or no treatment) before ex vivo, in situ MV. 
The IPML setup was used to ventilate these animals with the following ventilation 
parameters: Vt=5ml/kg, PEEP=3 cmH2O, RR=60 breaths/min. This resulted in the 
following experimental conditions: i) air + no treatment; ii) air + bLES; iii) acid + no 
treatment; iv) acid + bLES.   
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2.2.2. Intra-tracheal hydrochloric acid instillation 
Mice were randomized to receive either an intra-tracheal (i.t.) administration of HCl or 
air as a control, as previously described [9]. Briefly, mice were anesthetised with an intra-
peritoneal injection of ketamine (130 mg/kg; Sandoz, Quebec, Que., Canada) and 
xylazine (6 mg/kg; Bayer, Toronto, Ont., Canada). Once the proper depth of anesthesia 
was reached, mice were positioned dorsally on a vertical stand and their trachea was 
intubated with a 20-gauge catheter coupled with a fiber-optic stylet (BioLite intubation 
system for small rodents, BioTex, Inc., Houston, Tex., USA). Animals randomized to the 
acid instillation group were given 50 µl of 0.05 Ν HCl in a drop-wise fashion through the 
endotracheal tube. Animals randomized to the control group were intubated as described 
and allowed to breathe spontaneously through the tube. The total procedure took 
approximately 5 minutes. Mice were then extubated, positioned on a horizontal inclined 
stand and administered sub-cutaneous injections of buprenorphine (0.05-0.1 mg/kg) and 
1ml of sterile normal saline. Subsequently, mice were returned to the cage and allowed to 
recover for 4 hours with free access to water and food. Mice were carefully monitored 
during the 4 hours recovery period. 
2.2.3. Intra-tracheal surfactant instillation 
Mice were anesthetised with an intra-peritoneal (i.p.) injection of ketamine (130 mg/kg) 
and xylazine (6 mg/kg). Animals were then positioned dorsally on a vertical rodent stand 
and the trachea was intubated trans-orally with a 20-gauge catheter coupled with a fiber-
optic stylet (BioLite intubation system for small rodents, BioTex, Inc., Houston, Tex., 
USA). Mice randomized to the surfactant administration group were given 50 mg/kg 
bLES (BLES Biochemicals, London, Ont., Canada) in a drop wise fashion through the 
endotracheal tube. This natural, bovine lipid extracted surfactant is composed of 
approximately 97% phospholipids, 3% neutral lipids, and about 1% by weight proteins 
[21]. After the surfactant was spontaneously inhaled by the animals, mice were 
extubated, positioned on a horizontal inclined stand. To allow for peripheral surfactant 
distribution, based on preliminary experiments, mice were allowed to spontaneously 
breathe for 12-15 minutes before MV. Animals randomized to the no treatment group 
were intubated as described and allowed to breathe spontaneously.  
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2.2.4. Isolated and Perfused Mouse Lung setup  
Mice were ventilated for a total of 2 hours using the IPML setup. Following exogenous 
surfactant administration (or no treatment), the anesthetised mice were sacrificed with an 
additional i.p. injection of ketamine (200 mg/kg) and xylazine (10 mg/kg). A 
tracheostomy tube was then inserted and secured in the trachea, and the animals were 
subsequently connected to the IPML apparatus as described by Von Bethmann et al. [22]. 
Briefly, the heart and lungs were surgically exposed and the lungs were ventilated with a 
volume cycled, positive pressure ventilator (Flexivent, Scireq, Montreal, Que., Canada) 
with different ventilation strategies as described in detail under the experimental design 
section. Perfusate (RPMI lacking phenol red + 2% w/v low endotoxin grade Bovine 
Serum Albumin; Sigma, St. Louis, Mo., USA) was circulated into the pulmonary 
vasculature through a catheter inserted in the pulmonary artery and collected by a second 
catheter in the left ventricle. Once the lungs were cleared of all the blood, perfusate was 
delivered in a re-circulating fashion (rate 1ml/min) during the 2 hours of MV. One 
milliliter of perfusate was collected at baseline (time 0, immediately after vascular 
clearing and before perfusate re-circulation) and every 30 minutes of MV thereafter. 
Samples were frozen and stored at -80ºC for subsequent measurement of inflammatory 
mediators. Physiological parameters such as peak inspiratory pressure (PIP) and 
perfusion pressure were monitored throughout ventilation utilizing Chart v.4.12 software 
(AD Instruments, Castle Hill, Australia). 
2.2.5. Surfactant and total lung lavage protein measurements 
Immediately after MV using the IPML setup, lungs were lavaged with 3 x 1ml aliquots of 
0.9% NaCl solution with each aliquot instilled and withdrawn 3 times. The total lavage 
volume was recorded and average recoveries of lavage fluid were 2.7 mL and 2.8 mL for 
experiment 1 and experiment 2, respectively. Total lavage was then immediately 
centrifuged at 380 g for 10 min. at 4ºC to remove the cellular component, and the 
collected supernatant was termed total surfactant (TS). A 1 ml aliquot of TS was stored at 
-80ºC for cytokine and protein analysis. In order to separate the small aggregate sub-
fraction (SA) from the large aggregate (LA) sub-fraction, 1 ml of TS was centrifuged at 
40,000 g for 15 min at 4ºC. The LA pellet was then re-suspended in 0.3 ml of 0.9% NaCl, 
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while the supernatant represented the SA fraction. The leftover volume of TS was used 
for analysis of total surfactant pool size. TS, LA and SA were frozen and stored at -80ºC. 
Measurement of the phospholipid content in TS, LA and SA was performed by 
phosphorous assay on chloroform-methanol extracted samples, as previously described 
[23, 24]. Total protein content in lavage was assessed using a Micro BCA protein assay 
kit (Pierce, Rockford, Ill., USA) according to manufacturer’s instructions.  
2.2.6. Biophysical functional analysis of surfactant  
LA sub-fractions from animals within each experimental group were pooled together for 
functional analysis. An aliquot from each pooled sample was utilized to measure the total 
phospholipid content by phosphorous assay, while the remaining pooled LA was 
centrifuged at 40,000g for 15 min at 4ºC. The supernatant was then discarded and the 
purified LA pellet re-suspended in a buffer solution (1.5 mM CaCl2, 5 mM TRIS) to a 
final phospholipid concentration of 5 mg/ml. The surface activity of the LA samples was 
assessed using a computer-controlled captive bubble surfactometer (CBS, 3 runs for each 
pooled sample) as previously described [25, 26].  
2.2.7. Measurement of inflammatory mediators 
Interleukin-6 (IL-6) levels were measured in aliquots of lung lavage and in perfusate 
aliquots obtained at different time points using an enzyme-linked immunosorbent assay 
(ELISA) kit following manufacturer’s instructions (BD Biosciences, San Diego, CA., 
USA). A broader array of inflammatory mediators was measured in perfusate samples 
collected at the end of MV using a Milliplex Map mouse cytokine/chemokine panel 
(MPXMCYTO-70K-12; Millipore Corporation, Billerica, MA, USA) for the following 
12 analytes: eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-1β, IL-6, IL-13, interferon-γ-
induced protein 10 (IP-10), keratinocyte chemoattractant (KC), lipopolysaccharide-
induced CXC chemochine (LIX), monocyte chemotactic protein-1 (MCP-1), macrophage 
inflammatory protein 2 (MIP-2) and tumor necrosis factor-alpha (TNF-α). Samples were 
analyzed utilizing the Luminex® xMAP® detection system on the Luminex100 (Linco 
Research, St. Charles, Mo., USA) according to the manufacturer’s instructions. Perfusate 
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samples collected at the end of MV in experiment 2 were further analyzed for eicosanoids 
levels (8-isoprostane, prostaglandin E2, leukotriene B4, thromboxane B2) using 
colorimetric competitive enzyme immunoassay (EIA) kits (Cayman Chemical Company, 
Ann Arbor, MI, USA) according to manufacturer’s instructions.  
2.2.8. Statistical analysis 
All data are expressed as mean ± standard error of the mean (SEM). Statistical analyses 
were performed using the GraphPad Prism statistical software (GraphPad Software, Inc., 
La Jolla, CA., USA). Data were analysed with a t-test or one way ANOVA with a 
Tukey’s post hoc test when appropriate (experiment 1). For experiment 2, a two-way 
ANOVA (variables: presence of primary insult and treatment effects) followed by a one-
way ANOVA with a Tukey’s post hoc test was used to analyse the data. A repeated 
measures two-way ANOVA was performed when appropriate with a Bonferroni post hoc 
test. P < 0.05 was considered statistically significant. 
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2.3. Results 
2.3.1. Experiment  1. 
In experiment 1 the effects of exogenous surfactant administration on lung and systemic 
inflammation during MV of otherwise normal lungs were determined. Peak inspiratory 
pressure (PIP) was recorded throughout MV. PIP ranged between 20.62±1.6 cmH2O and 
22.6±2.7 cmH2O for the No Treatment group (time 0 and time 120min, respectively) and 
varied between 22.6±2.7 cmH2O and 26.3±2.7 cmH2O for the bLES group (time 0 and 
time 120min, respectively). Exogenous surfactant administration did not reduce PIP 
values in the surfactant treated group compared to No Treatment. Perfusion pressure was 
also monitored throughout MV and maintained between 4 and 6 mmHg for both groups 
(Fig. 2.1). 
 
 
Figure 2.1 Experiment 1. Perfusion pressure measured throughout MV. Values are 
expressed as mean ± SEM; n=6 per group. 
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Lavage Analysis  
Results reflecting local inflammation, as assessed by pulmonary permeability changes 
and inflammatory markers are shown in Table 2.1. The total protein content and IL-6 
levels in lung lavage collected at the end of MV were not affected by surfactant 
treatment, with no statistically significant differences noted in these values between bLES 
treated and non-treated groups. Recoveries of lung lavage fluid were not statistically 
significant between groups (data not shown). 
 
 
Mechanical Ventilation 
 No treatment bLES 
Total lavage protein 
(mg/kg body weight) 
13.4 ± 1.2 34.6 ± 18.9 
Lavage IL-6 (pg/mL) 136.8 ± 31.4 474.1 ± 233.8 
Table 2.1 Experiment 1. Total protein levels and IL-6 concentrations in lung lavage at 
the end of MV. Values are expressed as mean ± SEM; n=6 per group. 
 
Surfactant pool sizes of TS, LA and SA sub-fractions isolated from lung lavage for the 
two groups are shown in Figure 2.2A. As expected, TS pools were significantly higher in 
the bLES treated group compared to No Treatment mice. Similarly to TS values, LA and 
SA pools were significantly higher in the bLES group compared to the No Treatment 
group (Fig. 2.2A). The functional activity of the LA samples measured during four 
different dynamic compression-expansion cycles is shown in Figure 2.2B for each 
experimental group. No significant differences in surface tension were found between 
bLES treated and No Treatment mice for any of the cycles. Within each group, the 
minimum achievable surface tension was significantly higher during cycle 10 compared 
with cycles 1 and 2 (Fig. 2.2B). 
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Figure 2.2 Experiment 1. Surfactant recovery in lung lavage and surface activity of LA. 
A: surfactant pool size of TS, LA and SA sub-fractions measured by phosphorous assay. 
Data are expressed as amount of phospholipids/kg body weight. Within each sub-
fraction, *p<0.05 vs the No Treatment condition. B: minimum surface tension of pooled 
LA samples during different dynamic compression-expansion cycles. #p<0.05 versus 
cycle 1 and 2 within each experimental conditions. Values are expressed as mean ± 
SEM.; n=6 per group. 
 
Perfusate Analysis  
The concentration of IL-6 was measured in perfusate samples in order to assess the 
effects of exogenous surfactant on the development of systemic inflammation (Figure 
2.3). IL-6 levels were not detectable within the first 30 minutes of MV (time 0 and 30 
min; data not shown). A gradual increase in perfusate IL-6 was measured at 60 and 90 
minutes in both groups; however, there was no statistically significant difference in this 
cytokine level between bLES treated and No Treatment mice at any time point 
throughout MV.  
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Figure 2.3 Experiment 1. IL-6 levels measured in lung perfusate at 60, 90 and 120 min. 
Values are expressed as mean ± SEM.; n=6 per group.  
 
 
Perfusate concentrations of 11 cytokines/chemokines measured at the end of MV by 
multiplex assay are shown in Table 2.2. Perfusate IL-13 levels were not detectable (data 
not shown). There was no statistically significant effect of exogenous surfactant 
administration on cytokines/chemokines concentrations in perfusate, with no differences 
between No treatment and bLES groups. 
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 Mechanical Ventilation 
Mediator (pg/ml) No treatment bLES 
Eotaxin 42.8±3.6 42.7±6.5 
G-CSF 9.5±2.0 11.7±2.8 
GM-CSF 1.6±1.6 5.1±2.4 
IL-6 520.6±117.2 463.0±75.2 
IL-1 β 0.8±0.4 0.6±0.3 
KC 868.6±254.3 853.8±222.6 
LIX 71.3±14.8 66.1±11.4 
MCP-1 12.2±2.7 7.5±1.8 
MIP-2 753.9±193.8 658.5±167.8 
TNF-α 23.4±7.8 17.4±7.0 
IP-10 39.9±5.4 37.8±6.2 
Table 2.2 Experiment 1. Cytokine and chemokine analysis in lung perfusate at the end of 
MV. Data are expressed as mean ± SEM; n=6 per group. 
G-CSF=granulocyte colony-stimulating factor, GM-CSF= granulocyte-macrophage CSF, 
IL-6=interleukin-6, IP-10=interferon-γ-induced protein 10, KC=keratinocyte 
chemoattractant, LIX=lipopolysaccharide-induced CXC chemokine, MCP-1=monocyte 
chemotactic protein-1, MIP-2=macrophage inflammatory protein 2 and TNF-α=tumor 
necrosis factor-alpha. 
 
2.3.2. Experiment  2. 
In experiment 2, the effect of exogenous surfactant on systemic inflammation during MV 
was assessed in the presence of a pre-existing acid-induced lung injury/inflammation. 
Physiological parameters such as peak inspiratory pressure and perfusion pressure were 
monitored throughout ventilation as in experiment 1, and PIP values are shown in Figure 
2.4. Although all experimental groups were exposed to the same ventilation strategy, the 
peak inspiratory pressure was significantly higher in Acid injured mice compared to the 
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respective Air groups (Acid No Treatment vs Air No Treatment; Acid bLES vs Air 
bLES). Exogenous surfactant administration led to a significant increase in PIP values 
during the first hour of MV (10 to 75 min) in the Air bLES group compared to Air No 
Treatment group and, importantly, did not reduce PIP values in the Acid bLES group 
compared to Acid No Treatment group at any time point. Perfusion pressure was 
monitored during MV and maintained between 5 and 7 mmHg for all groups (Fig. 2.5). 
 
 
 
Figure 2.4 Experiment 2. Peak Inspiratory Pressure (PIP) was measured over the course 
of MV. Values are expressed as mean ± SEM. +p<0.05 versus Air No Treatment at the 
specific time point indicated, *p<0.05 versus the respective Air control at each time 
point; n=6 per group. 
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Figure 2.5 Experiment 2. Perfusion pressure measured throughout MV. Values are 
expressed as mean ± SEM; n=6 per group. 
 
Lavage Analysis  
Lung permeability, as reflected by total protein content in lung lavage (Table 2.3), was 
significantly higher in the acid injured animals versus the air control groups, whether they 
were given surfactant or not (Acid No Treatment vs Air No Treatment; Acid bLES vs Air 
bLES). No significant difference was noted between Air bLES versus Air No Treatment 
and Acid bLES versus Acid No Treatment. Similar results were observed for IL-6 
concentration in lung lavage (Table 2.3). Acid–instilled animals showed greater IL-6 
levels in lavage compared to the respective air-instilled controls. Exogenous surfactant 
did not affect lavage IL-6 levels in both air groups (Air bLES vs Air No Treatment); 
however, there was a significantly higher cytokine concentration in the lavage of Acid 
bLES mice compared to the Acid No Treatment group. Recoveries of lung lavage fluid 
were not statistically significant between groups (data not shown). 
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 Air Acid 
 
No 
treatment 
bLES 
No 
treatment 
bLES 
Total lavage protein 
(mg/kg body weight) 
46.3 ± 8.1 32.8 ± 5.6 215.4 ± 21.1* 
194.3 ± 
26.9* 
Lavage IL-6 
(pg/mL) 
237.8 ± 72.9 
635.1 ± 
120.2 
5034.9 ± 
653.4* 
6775.5 ± 
1476.1*,# 
Table 2.3 Experiment 2. Total protein levels and IL-6 concentrations were measured in 
lung lavage at the end of MV. Data are expressed as mean ± SEM; n=6 per group. 
*p<0.05 versus the respective Air control, #p<0.05 versus Acid no Treatment.  
 
Surfactant sub-fractions and the surface activity of isolated LA are shown in Figures 2.6A 
and B respectively. Acid instillation did not change TS, LA and SA pool sizes compared 
to their respective Air control groups (Fig. 2.6A). This was similar for both not treated 
and surfactant treated groups. As expected and observed in experiment 1, total surfactant 
and LA values were significantly higher in surfactant treated groups than non-surfactant 
treated controls (Air bLES vs Air No Treatment; Acid bLES vs Acid No Treatment). 
There was no difference in SA values among the various experimental groups.  
There were no statistically significant differences noted between any of the experimental 
groups in the biophysical activity of the LA samples (Fig. 2.6B). Within some of the 
groups, however, significant differences in surface tension were measured between the 
different dynamic cycles. In particular, surface tension was significantly higher during 
compression-expansion of cycles 5 and 10 when compared to cycle 1 within the acid 
instilled groups (in both Acid No Treatment and Acid bLES). LA from the Air No 
Treatment and Air bLES groups maintained low surface tension values throughout the 10 
dynamic compression-expansion cycles.  
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Figure 2.6 Experiment 2. Surfactant recovery in lung lavage and surface activity of 
crude LA. A: surfactant pool size of TS, LA and SA sub-fractions measured by 
phosphorous assay. Data are expressed as amount of phospholipids/kg body weight. 
Within each sub-fraction,*p<0.05 versus the respective No Treatment condition. B: 
surface tension of pooled LA samples during different dynamic compression-expansion 
cycles. §p<0.05 versus cycle 1 within each experimental condition. Values are expressed 
as mean ± SEM; n=6 per group. 
 
Perfusate Analysis  
To test the hypothesis of a role for exogenous surfactant in down-modulating systemic 
inflammation in ALI, sequential lung perfusate samples, as a surrogate for systemic 
inflammation, were analyzed for IL-6 concentrations. As shown in Figure 2.7, there were 
significantly higher levels of IL-6 in the perfusate of acid-instilled mice compared to the 
respective air-instilled controls at every time point (0, 30, 60, 90, 120 min; Acid No 
Treatment vs Air No Treatment; Acid bLES vs Air bLES). Perfusate IL-6 levels were not 
significantly affected by exogenous surfactant administration, with no differences 
between Air bLES and Air No Treatment and no change between Acid bLES and Acid 
No treatment.  
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Figure 2.7 Experiment 2. IL-6 levels measured in lung perfusate at 0, 30, 60, 90, 120 
min. Data are expressed as mean ± SEM. *p<0.05 versus respective Air control at each 
time point; n=6 per group. 
 
Lung perfusate samples collected at 120 min were further analyzed for a wider array of 
cytokines/chemokines. Among the 12 mediators measured (Table 2.4), IL-13 levels were 
not detectable (data not shown), while there were significantly greater levels of eotaxin, 
IL-6, KC, MIP-2 in acid-instilled animals compared to the respective air instilled control.  
Overall, exogenous surfactant administration did not affect eotaxin, GM-CSF, IL-6, IL-
1β, KC, TNF-α and IP-10 levels, with no statistical difference between the bLES and No 
Treatment group in both Air and Acid instilled mice.  
A statistically significant increase of MIP-2 levels in the perfusate of Acid bLES mice 
was determined compared to Acid No Treatment, as well as significantly higher perfusate 
levels of G-CSF, LIX and MCP-1 in acid injured mice treated with surfactant compared 
to the Air bLES.  
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 Air Acid 
Mediator 
(pg/ml) 
No 
treatment 
bLES No treatment bLES 
Eotaxin 17.4±1.3 25.7±0.9 135.2±13.6* 142.8±15.9* 
G-CSF 45.9±10.5 59.4±3.4 890.8±75.8 1270.3±187.8* 
GM-CSF 0 0 13.4±2.8 16.3±2.2 
IL-6 567.7±62.7 1119.0±99.1 8303.2±323.6* 10720.1±764.2* 
IL-1 β 1.0±0.40 0.2±0.1 0.3±0.1 3.2±0.6 
KC 579.2±65.8 907.0±75.4 3617.2±174.3* 6212.7±504.8* 
LIX 113.7±11.1 98.3±13.0 284.6±17.9 447.4±31.9* 
MCP-1 12.9±1.8 30.9±4.9 337.4±26.2 558.0±71.5* 
MIP-2 584.4±68.2 725.7±41.9 1840.2±76.7* 3113.4±204.8*,# 
TNF-α 63.4±11.6 72.2±7.0 119.7±3.1 143.3±8.1 
IP-10 32.9±3.6 40.8±1.7 391.3±80.8 283.3±27.7 
Table 2.4 Experiment 2. Cytokine and chemokine measured in lung perfusate at the end 
of MV. Data are expressed as mean ± SEM; n=6 per group. *p<0.05 versus respective 
Air control, #p<0.05 versus Acid No Treatment.   
G-CSF=granulocyte colony-stimulating factor, GM-CSF= granulocyte-macrophage CSF, 
IL-6=interleukin-6, IP-10=interferon-γ-induced protein 10, KC=keratinocyte 
chemoattractant, LIX=lipopolysaccharide-induced CXC chemokine, MCP-1=monocyte 
chemotactic protein-1, MIP-2=macrophage inflammatory protein 2 and TNF-α=tumor 
necrosis factor-alpha. 
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Finally, in order to further characterize the effect of exogenous surfactant administration 
on lung-derived mediators in perfusate, eicosanoids levels were also measured at the 120 
min. time point (Table 2.5). Although increased levels of thromboxane B2 and 
prostaglandin E2 were recorded in the perfusate of acid-instilled animals compared to 
their respective Air controls, these changes did not reach statistical significance. 
Perfusate concentrations of 8-isoprostane were significantly higher in the acid injured 
groups compared to air controls. Surfactant treatment did not affect thromboxane B2 and 
8-isoprostane concentrations. Prostaglandin E2 levels were significantly elevated only in 
the perfusate of Acid bLES mice compared to Air bLES controls. Leukotriene B4 levels 
were increased in the perfusate of Acid bLES mice but this difference failed to be 
statistically significant. 
 
 Air Acid 
Mediator (pg/ml) 
No 
treatment 
bLES 
No 
treatment 
bLES 
Prostaglandin E2 14.3±2.0 26.8±3.9 147.4±40.3 221.7±89.2* 
Leukotriene B4 14.4±5.2 10.6±5.3 13.1±7.3 41.9±12.3 
Thromboxane B2 52.7±10.1 67.8±12.9 109.9±24.8 134.9±43.6 
8-Isoprostane 11.3±1.6 19.7±3.0 47.2±8.1* 70.4±12.5* 
Table 2.5 Experiment 2. Concentrations of prostaglandin E2, leukotriene B4, 
thromboxane B2 and 8-isoprostane measured in lung perfusate samples collected at the 
end of MV. Data are expressed as mean ± SEM; n=6 per group. *p<0.05 versus the 
respective Air control. 
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2.4. Discussion  
The overall objective of this study was to evaluate the anti-inflammatory effects of 
exogenous surfactant when administered prior to mechanical ventilation, either in the 
absence (experiment 1) or in the presence (experiment 2) of an initiating pulmonary 
insult. For both lung injury models, the IPML setup was utilized to specifically evaluate 
the contribution of ventilation to the development of systemic inflammation. MV of 
normal lungs resulted in the release of IL-6 (locally) into the airspace and several 
mediators (systemically) in the perfusate. Surfactant administration, however, was not 
effective in reducing the systemic inflammation associated with MV. Conventional 
ventilation of HCl instilled mice led to higher levels of both IL-6 and total protein in 
lavage, and significantly higher levels of pro-inflammatory mediators in perfusate 
without any beneficial effect of bLES instillation. Notably, significantly higher lavage 
IL-6 and perfusate MIP-2 concentrations were observed in acid-injured mice receiving 
bLES, compared to Acid-No Treatment controls. Based on these results, it was concluded 
that administration of exogenous surfactant prior to MV does not reduce the systemic 
inflammation associated with lung injury in these models.  
An important feature of the current study was to examine the effects of surfactant therapy 
in two different models. Analysis of the data showed important differences between the 
models, such as the degree of lung edema. Mechanical stretch of uninjured lungs did not 
affect lung permeability, whereas acid injured mice had increased total lavage proteins 
after two hours of MV. Another aspect that distinguishes the two models is represented 
by different levels of pulmonary and perfusate inflammation, which becomes particularly 
evident when comparing cytokine levels measured in the perfusate of the MV only, No 
Treatment group to the cytokine levels of the Acid No Treatment group. For example, 
MV of normal lungs caused a moderate increase in circulating Eotaxin, IL-6, KC and 
MIP-2, while acid instilled animals subjected to conventional MV had perfusate 
concentrations of these mediators that were at least two times greater. Given the greater 
inflammation characterizing the acid-injury model and the important role of lipid 
mediators in the development and progression of lung injury [27-32], eicosanoids levels 
were analyzed only on samples from experiment 2. Unambiguous conclusions about the 
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effects of exogenous surfactant on systemic inflammation were therefore inferred from 
two experimental models with very different characteristics. This allowed us to rule out 
possible causes for the lack of efficacy of our treatment (such as presence/lack of pre-
existing injury, specific effects of ventilation), and strengthened the understanding of the 
biological response. 
Exogenous surfactant administration has been extensively investigated as a potential 
adjunctive therapy in acute lung injury [33-36]. The traditional approach with surfactant 
treatment has been to evaluate its efficacy in terms of physiological and biophysical 
improvements. Many experimental studies have in fact demonstrated that exogenous 
surfactant instilled after the onset of ventilation improved oxygenation, lung volume and 
compliance; moreover, it improved the surface tension reducing properties of the 
surfactant recovered from lung lavage subsequent to administration [15, 37, 38]. 
Nevertheless, despite this encouraging experimental evidence, clinical trials showed no 
improvement in mortality in surfactant treated patients even in the presence of an initial 
improvement in oxygenation [16, 18]. It is possible that surfactant treatment in the 
previous studies was administered too late into ALI development; therefore earlier 
surfactant administration prior to or at the onset of MV could be more effective at 
mitigating disease progression. Since mortality can be improved by ameliorating 
ventilation – induced systemic inflammation [39], it was our interest to investigate 
whether exogenous surfactant could mitigate the effects of MV thereby down-modulating 
inflammation. 
To our knowledge, the effect of surfactant on ventilation-induced release of inflammatory 
mediators in perfusate of an IPML model has been specifically addressed in two previous 
studies. Stamme and colleagues [40] showed elevated TNFα and IL-6 concentrations in 
the perfusate of surfactant treated animals compared to controls, in their mouse model of 
high pressure ventilation. In contrast, our group has shown a reduced level of 
inflammatory cytokines in perfusate due to elevated endogenous surfactant in an LPS 
model of injury [20]. Together with the current study in which surfactant did not impact 
inflammation in two models of injury, these data illustrate the complexity of surfactant 
treatment in which specific details of the experimental model may impact outcome. 
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Furthermore, such details are obviously important to understand in the context of a 
potential clinical utilization of surfactant treatment to down-regulate systemic 
inflammation as well as to understand the mechanisms by which surfactant may affect 
inflammation. 
Despite the lack of effect of surfactant treatment in our study, we speculate that 
mitigation of MV induced inflammation is still the best approach for an early 
intervention. Our data support earlier studies which showed that cytokines can be 
detected in perfusate rapidly after the onset of ventilation [22, 41]. This loss of alveolar 
and systemic cytokine compartmentalization can lead to peripheral organ dysfunction, a 
condition of difficult clinical management. Therefore, targeting the lung with anti-
inflammatory agents prior to MV may be a successful treatment option leading to 
improved outcomes. In this respect, surfactant could be utilized as a carrier for delivering 
lung specific anti-inflammatory agents prior to MV in future studies. 
Along with the strengths of the present study, some limitations need to be addressed. Due 
to the lack of blood perfusion in the IPML setup, the lungs were not exposed during ex 
vivo MV to circulating soluble factors and immune cells which could have affected the 
progression of the injury. Moreover, ex vivo ventilation of perfused lungs did not favor 
the use of severe lung injury models, due to potential technical failure of the preparation. 
Consequently, the injury from ventilation was mild to moderate, thereby explaining the 
lack of change in surface tension or surfactant pool sizes. It is believed, however, that 
these limitations of the IPML setup were counter balanced by the advantage of 
specifically isolating lung-derived mediators released into the circulation, without the 
confounding contribution of systemic factors to the development of inflammation. Intra-
tracheal instillation was also used for administering surfactant, ensuring the presence of 
large amounts of active material in the airspace before ventilation, as shown by higher 
levels of TS and LA in the lung lavage of treated animals. It should be acknowledged, 
however, that some inadequate distribution of surfactant might have occurred following 
instillation. Obstruction of smaller airways, with consequent heterogeneous lung inflation 
and regional over-distension might have been responsible for the increase in PIP 
(experiment 2, Air treated groups), and for the non-significant trend towards higher 
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lavage IL-6 levels in the surfactant treated groups. Nevertheless, the instilled surfactant 
retained excellent biophysical properties as shown by the very low minimum surface 
tension achieved during dynamic compression-expansion of the crude LA. Overall, we 
believe that instillation did not account for the lack of efficacy of our treatment.  
In conclusion, this study expands the knowledge about exogenous surfactant treatment. It 
specifically focuses on the anti-inflammatory effects of a lung targeted therapy 
administered prior to MV on the development of systemic inflammation using two 
different mouse models. Although our data suggest a lack of efficacy for exogenous 
surfactant in down-modulating inflammation, future studies might focus on surfactant as 
a carrier for anti-inflammatory drugs or antibiotics in order to better interfere with ALI 
progression. 
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CHAPTER 3:  
Lack of matrix metalloproteinase-3 in mouse models of lung injury 
ameliorates the pulmonary inflammatory response in female but not in 
male mice. 
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3.1. Introduction  
Acute lung injury (ALI) is a pulmonary inflammatory disorder with a mortality of 
approximately 40% [1, 2]. Clinically, ALI is defined by the presence of bilateral infiltrates 
on chest radiograph, alveolar edema in the absence of cardiac failure, and hypoxemia [3, 
4]. Despite a relatively simplistic clinical definition, ALI pathophysiology is complex, with 
a variable disease progression, and many different insults, such as bacterial pneumonia or 
gastric acid aspiration, capable of initiating lung injury [5, 6]. Within this complex disease 
process, pulmonary inflammation represents a key aspect of ALI pathophysiology that is 
common to all patients regardless of the initiating insult [7, 8], and which is strongly related 
to outcomes of ALI [9]. Numerous experimental studies have shown that strategies capable 
of modulating the lung inflammatory response greatly affect disease progression to 
systemic inflammation and consequent multi-organ failure, the main cause of death in ALI 
[10–15].  
Clinical evidence for the importance of lung inflammation in ALI stems from clinical trials 
over the past decade, which consistently demonstrated that lower indices of lung 
inflammatory mediators were associated with diminished systemic inflammation, and 
subsequent lower mortality [16, 17]. In these trials, the decrease in pulmonary 
inflammation resulted from the use of non-injurious strategies of mechanical ventilation, 
the main supportive therapy in ALI [16, 17]. Since then, however, no other lung-targeted 
pharmacological or anti-inflammatory treatment has been identified that is capable of 
reducing mortality [18, 19], thereby stressing the importance of further research into key 
modulators of pulmonary inflammation in ALI. 
One potential key mediator of pulmonary inflammation is matrix metalloproteinase-3 
(MMP-3), a protease expressed in the lung by alveolar macrophages (AM), alveolar 
epithelial cells, and fibroblasts [20–22]. MMP-3 is a member of the matrix 
metalloproteinases (MMPs) family, which consists of over 20 extracellular, zinc-
dependent proteolytic enzymes involved in several physiological processes such as matrix 
turnover, tissue repair, and inflammation [23–25]. Interestingly, metalloproteinase activity 
and expression levels are often elevated in injured tissues and in inflammatory conditions 
such as asthma, sepsis, and ALI [26–30]. Specifically, recent clinical studies have 
94 
 
confirmed elevated MMPs levels in lavage samples from patients with ALI; importantly, 
detectable lavage levels of a specific member of this family, namely MMP-3, were 
associated with severity of ALI, distal organ failure, and mortality [27, 31]. In addition to 
this clinical evidence, two experimental studies suggest a potential role for MMP-3 in ALI 
[32, 33]. These studies showed that, compared to wild type animals, mice lacking Mmp3 
expression had lower neutrophils and total protein accumulation within the lung following 
intra-tracheal instillation of the chemokine MIP-2 and in a model of immunoglobulin G 
immune-complex-induced lung injury [32, 33]. Although supportive of a role for MMP-3 
in ALI, these studies have utilized neutrophil-dependent models of ALI that lack clinical 
relevance, since they do not resemble any of the most common initiating insults in the 
pathogenesis of this disorder. It is, therefore, necessary to investigate the role of MMP-3 
in clinically relevant models of ALI, with a specific focus on pulmonary inflammation, as 
it appears to be a key driving factor in disease progression. 
It was hypothesized that MMP-3 is a key mediator in the pathogenesis of ALI by affecting 
pulmonary inflammation. To test this hypothesis, male and female wild type mice 
(Mmp3+/+) and mice lacking Mmp3 expression (Mmp3-/-) were exposed to two clinically 
relevant models of lung injury: i) a model of lipopolysaccharide-induced lung injury, 
resembling bacterial pneumonia, and ii) a model of acid-induced ALI, which mirrors lung 
injury due to gastric acid aspiration. Each model reproduces major pathophysiological 
events in ALI, such as the intra-pulmonary accumulation of proteinaceous edema fluid, the 
increased pulmonary release of cytokines and chemokines by resident alveolar 
macrophages and lung epithelial cells, and the recruitment of inflammatory neutrophils to 
the injured lung [5]. 
Interestingly, initial analyses showed a more prominent role of MMP-3 in female mice; 
therefore, data from female mice and from male mice have been analyzed separately, as 
distinct data sets. A sex-dependent role of MMP-3 in lung inflammation was observed in 
both ALI models, which led to initial in vitro investigations into mechanisms and 
inflammatory cell population (AM) potentially contributing to these findings. Experiments 
were performed using bone marrow-derived macrophages (BMDMs) as a surrogate for 
AM. Questions on possible inherent differences in the inflammatory response of 
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male/female Mmp3+/+ and Mmp3-/- BMDMs, and on the potential effect of 17β-estradiol 
(E2), were preliminarily addressed in this work. 
 
 
3.2. Methods 
3.2.1. Animal procedures and experimental design 
Mice lacking the expression of Mmp3 (Mmp3-/-) were originally generated as described by 
Mudgett JS et al. [34].; breeding pairs of Mmp3-/- mice were kindly provided by Dr. G.P. 
Downey (National Jewish Hospital, Denver, Colorado) to initiate and re-derive a pathogen 
free colony of Mmp3+/+ and Mmp3-/- mice. All the animals were group housed in a research 
animal facility, exposed daily to a 12 hours light/dark cycle and allowed unrestricted access 
to standard chow food and water. 
A total of 109 female and male Mmp3+/+ and Mmp3-/- mice were utilized for three separate 
experiments – a model of lipopolysaccharide-induced lung injury (experiment 1), a model 
of acid-induced lung injury (experiment 2), and BMDMs isolation (experiment 3) – and all 
animal procedures were approved by the Animal Use Subcommittee at Western University 
(protocol number: 2010-272). 
3.2.2. Experiment 1: Lipopolysaccharide induced lung injury 
A total of 47 Mmp3+/+ and Mmp3-/-, female and male mice (13.9 ± 0.4 weeks old; average 
± sem) were randomized to receive an intra-tracheal (i.t.) instillation of lipopolysaccharide 
(LPS from E.Coli, 0111:B4, 20 µg/mouse; Sigma, St. Louis, Mo., USA) or saline (0.15M 
NaCl solution) as a control for this model. Considering that the data were analyzed by sex, 
for both female and male mice the following 4 experimental groups were obtained: i) 
Mmp3+/+ Saline, ii) Mmp3+/+ LPS, iii) Mmp3-/- Saline, iv) Mmp3-/- LPS. 
Mice were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg; Sandoz, 
Quebec, Que., Canada) and medetomidine (1 mg/kg; Orion Corporation, Espoo, Finland). 
Once adequate sedation was achieved, mice were placed dorsally on a vertical, slightly 
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inclined stand, and the oral cavity was opened to visualize the vocal cords. Subsequently, 
a 20-gauge catheter combined with a fiber-optic stylet (BioLite intubation system for small 
rodents, BioTex, Inc., Houston, Tex., USA) was inserted through the vocal cords into the 
trachea. Mice randomized to the LPS group received 40 µL of a 0.5 mg/mL LPS solution 
in sterile saline (0.15M NaCl), instilled drop-wise through the endotracheal tube. Mice 
randomized to the Saline group were intubated and received 40 µL of a sterile 0.15M NaCl 
solution. The whole procedure required approximately 15 minutes. Mice were then 
extubated, injected subcutaneously with 0.5 mL sterile saline and immediately returned to 
their cage. Preliminary studies performed during development of the model determined 
that mice did not require any analgesia following instillation. Within 30 minutes from the 
injection of the anesthetic mix, mice received an intra-peritoneal injection of atipamezole 
(1 mg/kg; Zoetis, Florham Park, NJ, USA), the reversal agent for medetomidine. Mice were 
left to recover for a total of 18 hours with free access to water and food. At the end of the 
18 hours, mice were sacrificed with an intraperitoneal injection of sodium pentobarbital 
(110 mg/kg; Lundbeck, Valby, Denmark) followed by exsanguination, and processed for 
various analyses as described in sections 3.2.4 to 3.2.7. 
3.2.3. Experiment 2: Acid-induced lung injury  
A total of 44 Mmp3+/+ and Mmp3-/-, female and male mice (12.7 ± 0.5 weeks old) were 
randomized to receive an intra-tracheal instillation of hydrochloric acid (HCl) or air as a 
control. Similar to Experiment 1, the data from each sex were analyzed as different data 
sets. For both female and male mice, the following 4 experimental groups were analyzed: 
i) Mmp3+/+ Air, ii) Mmp3+/+ Acid, iii) Mmp3-/- Air, iv) Mmp3-/- Acid. 
An intraperitoneal injection of ketamine (100 mg/kg; Sandoz, Quebec, Que., Canada) and 
xylazine (5 mg/kg; Bayer, Toronto, Ont., Canada) was given to anesthetize mice and 
subsequently proceed with the endotracheal intubation as described above (under 
‘lipopolysaccharide-induced lung injury’). Mice randomized to acid instillation received 
50 µL of 0.05N HCl, instilled intra-tracheally in a drop-wise fashion. Mice randomized to 
the air group were intubated as described and allowed to spontaneously breathe through 
the tube. Overall, the procedure lasted about 15 minutes. Mice were then extubated, put on 
an inclined stand and injected subcutaneously with buprenorphine (0.05-0.1 mg/kg 
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Animalgesic Labs Inc., Millersville, MD, USA) and 0.3 mL sterile saline. Mice were then 
returned to their cage and 30 minutes after the injection of anesthetic, they were injected 
intra-peritoneally with atipamezole (1 mg/kg), reversal agent for xylazine. 
Mice were allowed to recover for 4 hours, with free access to food and water, and sacrificed 
at the end of the recovery period with an intraperitoneal injection of a ketamine (200 
mg/kg)-xylazine (10 mg/kg) solution followed by exsanguination. 
3.2.4. Lung lavage isolation and total protein analysis 
At the end of their respective recovery periods (18 hours for LPS-induced lung injury, 4 
hours for acid-induced lung injury), mice were given a euthanizing dose of anesthetic as 
previously described, and placed in a supine position. When deep anesthesia was attained, 
the abdominal content and thorax were exposed through an abdominal midline incision, 
and exsanguination was performed through excision of the inferior vena cava. A 
tracheostomy tube was subsequently inserted and secured in the trachea, the diaphragm cut 
and the chest wall opened via a midline incision to expose the lungs. Lungs were then 
lavaged with 3 × 1 mL aliquots of saline, and each aliquot was instilled and withdrawn 3 
times. The total volume of lavage fluid collected from each mouse was recorded. Lung 
lavage was immediately centrifuged at 380 g for 10 minutes at 4˚C to isolate the cell pellet; 
the supernatant was collected and 4 × 0.25 mL aliquots were frozen at -80˚C for analyses 
of inflammatory mediators.  
Measurements of total protein content in lavage were also performed on this supernatant 
using a Micro BCA protein assay kit (Pierce, Rockford, Ill., USA), as per manufacturer’s 
instructions. 
3.2.5. Lavage cell analysis 
Following centrifugation of lavage samples, the cellular component was isolated and 
resuspended in Plasmalyte (300 to 500 µL depending on cell density). An aliquot of cell 
suspension was mixed with an equal volume of trypan blue to assess viability through 
trypan blue exclusion, and subsequently utilized to determine total cell counts with a 
hemocytometer and light microscopy. Aliquots of the resuspended cell pellet were also 
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spun down on cytospin slides at 1000 rpm for 6 minutes at room temperature, stained with 
Hemacolor® stain (Harleco, EMD Chemicals Inc., Gibbstown, NJ, USA) and utilized to 
perform differential cell counts under light microscopy. Specifically, 5 fields were counted 
and averaged for each slide, and the relative percentage of each inflammatory cell type was 
calculated. The absolute number of neutrophils in lavage was then obtained by multiplying 
percentages by the total cell number previously determined. 
3.2.6. Measurements of MMP-3 and inflammatory mediators in lung lavage 
Total MMP-3 levels were measured in lavage aliquots from experiment 1 and 2, using a 
commercially available enzyme-linked immune-sorbent assay (ELISA) according to 
manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA). 
Lavage interleukin-6 (IL-6) levels were also assessed through the use of a mouse IL-6 
ELISA (BD Biosciences, San Diego, Ca., USA) according to manufacturer’s instructions. 
An array of inflammatory cytokines and chemokines was measured in lung lavage samples 
from both injury models. For both experiment 1 and 2, mouse Milliplex multi-analyte 
panels (Map) (MCYTOMAG-70K, Millipore Corporation, Billerica, MA, USA) were 
utilized to measure lavage levels of the following cytokine/chemokine: granulocyte colony 
stimulating factor (G-CSF), interleukin 10 (IL-10), keratinocyte chemoattractant (KC), 
monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 2 (MIP-2), 
and tumor necrosis factor alpha (TNF-α). Samples analysis was performed on the 
Luminex® xMAP® detection system on the Luminex100 (Linco Research, St. Charles, Mo., 
USA), as per manufacturer’s protocol. 
3.2.7. Experiment 3: Isolation of Mmp3+/+ and Mmp3-/- bone marrow-derived 
macrophages 
Bone marrow-derived macrophages (BMDMs) were isolated from the femurs and tibias of 
mice as previously described [35]. Briefly, a total of 18 Mmp3+/+ and Mmp3-/- mice (19.9 
± 1.7 weeks old) were sacrificed with an intraperitoneal injection of sodium pentobarbital 
(110 mg/kg) and exsanguinated. The femur and tibia of both hind legs were isolated, the 
soft tissue was removed, and the ends of each bone were cut off before placing each pair 
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of long bones in a 0.65 mL Eppendorf tube with a punctured bottom. Each one of these 
tubes was then placed into a 1.5 mL Eppendorf, thereby  allowing for the collection of the 
bone marrow cell pellet upon centrifugation of the bones at 2000 g for 1 minute at 4˚C. 
After lysis of red blood cells and subsequent wash with cold, sterile 1x PBS, bone marrow 
samples from each mouse were pulled together and centrifuged at 400 g, for 10 minutes, 
4˚C, and the resulting cell pellet was then resuspended in macrophage differentiation media 
(Mac media: RPMI 1640, 10% fetal bovine serum, 2 mM glutamine, 50 units/mL 
penicillin, 50 µg/mL streptomycin, and 30% L-cell supernatant as a source of monocyte-
colony stimulating factor). Bone marrow-derived cells were seeded and cultured in a 100 
mm Petri dish at 37˚C with 5% CO2 for 24 hours; at the end of this time, the non-adherent 
and loosely adherent cells were transferred to a 150 mm tissue culture dish with fresh Mac 
media, and cultured as previously described. Following a 7 days culture period, cells were 
fully differentiated into BMDMs and ready for experimental use. 
All reagents used for the culture of bone marrow derived macrophages were provided by 
Gibco® (Life Technologies, Grand Island, NY, USA), unless otherwise specified. L-cell 
supernatant was a generous gift of Dr. Gill (Western University, London ON, Canada). 
3.2.8. In vitro stimulation of Mmp3+/+ and Mmp3-/- bone marrow-derived 
macrophages 
The effects of LPS or a combination of LPS and estrogen were assessed in vitro on BMDMs 
isolated as described above. Fully differentiated BMDMs from male and female Mmp3+/+ 
and Mmp3-/- mice were harvested and 2×105 cells per well were seeded in a 24 well plate. 
The following day, macrophage differentiation media was substituted with stimulation 
media (RPMI 1640, 10% fetal bovine serum, 2 mM glutamine, 50 units/mL penicillin, 50 
µg/mL streptomycin) and BMDMs were exposed to one of the following conditions: i) 
control – media only, ii) 0.1µg/mL LPS (E.Coli, 0111:B4, Sigma, St. Louis, Mo., USA), 
iii) 1µg/mL LPS, iv) 10µg/mL LPS. BMDMs were stimulated at 37˚C, 5% CO2 for 18 
hours. At the end of the stimulation period, individual cell supernatants were collected, 
spun at 380 g for 10 minutes at 4˚C and frozen at -80 ˚C for subsequent analysis of IL-6 
levels. BMDMs from the stimulated 24 well plate were lysed on ice in lysis buffer (0.5% 
Sodium dodecyl sulfate, 50 mM Tris pH 7.5, 1 mM EDTA) with protease inhibitor 
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(cOmplete, Mini, EDTA-free, Roche Diagnostic GmbH, Mannheim, Germany) for 
measurements of total protein content (Micro BCA protein assay kit, Pierce, Rockford, Ill., 
USA). IL-6 levels of each individual cell supernatant were then normalized by the 
corresponding total protein content, to account for differences in total cell numbers 
between wells. A total of three independent experiments were performed. 
In a second set of experiments, differentiated BMDMs from female Mmp3+/+ and Mmp3-/- 
mice were harvested and 2×105 cells per well were seeded in a 24 well plate to be 
stimulated in the presence of 17-β estradiol (E2, Sigma, St. Louis, Mo., USA). On the next 
day, stimulation media was utilized to expose BMDMs to one of the following conditions: 
i) control media (with vehicle), ii) 0.1nM E2, iii) 1nM E2, iv) 10nM E2, v) 1µg/mL LPS, 
vi) 0.1nM E2 + 1µg/mL LPS, vii) 1nM E2 + 1µg/mL LPS, and viii) 10nM E2 + 1µg/mL 
LPS. Following 18 hours, cell supernatants were collected for IL-6 analysis and total 
protein content was assessed on cell lysates, as previously described. A total of three 
independent experiments were performed. 
3.2.9. Statistical analysis 
All data are expressed as mean ± standard error of the mean (SEM). GraphPad Prism 
statistical software (La Jolla, CA, USA) was utilized to perform statistical analyses. Data 
were analyzed using a two-way ANOVA (variables: genotype and treatment) followed by 
a one-way ANOVA with a Tukey’s post-hoc test. When appropriate, an unpaired two tailed 
Student’s t-test was utilized for analysis. P<0.05 was considered statistically significant.  
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3.3. Results  
3.3.1. Experiment 1: Lipopolysaccharide-induced lung injury 
Lavage MMP-3 
The role of MMP-3 in ALI was first assessed utilizing an 18-hour model of LPS-induced 
lung injury, in which Mmp3+/+ and Mmp3-/- mice of both sexes received an intra-tracheal 
administration of LPS or saline as a control.  
Total MMP-3 was measured in lavage samples from Mmp3+/+ mice. The results in figure 
3.1A show significantly higher lavage MMP-3 concentrations in LPS-injured mice 
compared to Saline controls. Given the use of both female and male mice for this study, 
the data was subsequently analyzed by sex. Notably, female Mmp3+/+ mice showed 
significantly elevated total MMP-3 following LPS injury compared to Saline (Fig. 3.1B); 
however MMP-3 concentrations in male, LPS-instilled Mmp3+/+ mice were not 
significantly higher than the respective Saline control (Fig. 3.1C). In light of this difference 
in results from female and male mice, the remaining of the experimental data was analyzed 
separately by sex. 
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Figure 3.1 Experiment 1: MMP-3 levels measured in lung lavage samples from Mmp3+/+ 
mice, 18 hours after intra-tracheal saline or LPS instillation. A: Lavage MMP-3 levels 
assessed in all Mmp3+/+ mice, n=11-12 per group; B: in female Mmp3+/+ mice, n=5-6 per 
group; C: in male Mmp3+/+ mice, n=6 per group. Data are expressed as mean ± SEM; 
*p<0.05 vs Saline control. 
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Lavage protein 
The average lavage volume recovered from all animals was 2.9 ± 0.02 mL, with no 
significant differences among groups (data not shown). Total protein content in lavage is 
shown in Table 3.1. No differences due to genotype were observed for Saline-instilled mice 
of both sexes. Overall, no significant differences were observed in total lavage protein of 
LPS-instilled Mmp3+/+ and Mmp3-/- mice compared to their respective Saline controls. 
Similar results were observed in both sexes, although female LPS-injured Mmp3+/+ mice 
appeared to have higher lavage protein than Saline control, but this difference did not reach 
significance. The genotype had no significant effect on this outcome following LPS 
instillation. 
  
 
Table 3.1 Experiment 1: Total protein content assessed in lavage from Mmp3+/+ and 
Mmp3-/- mice of either sex at the end of the 18 hours recovery period. Data are expressed 
as mean ± SEM; n=5-6 per group. 
 
Lavage inflammatory cells 
Pulmonary inflammation associated with this model of ALI was first investigated through 
the analysis of the lung lavage cellular infiltrate. Results in figure 3.2A and B showed no 
differences at baseline (Saline instillation) due to genotype in female mice. A higher but 
not significantly different total cell number was found in female, LPS-injured Mmp3+/+ and 
Mmp3-/- mice compared to the respective Saline controls, with no effect of the genotype 
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(Fig. 3.2A). Similarly, determination of total PMN cells in lavage showed a non-significant 
trend toward higher neutrophils in female Mmp3+/+ and Mmp3-/- mice exposed to LPS, 
with no differences due to genotype (Fig. 3.2B).  
In male mice, no differences due to genotype were found in the total number of cells (Fig. 
3.2C) and of PMN (Fig. 3.2D) in the lavage of Saline-instilled controls. The increase in 
lavage cell number was statistically significant in male Mmp3+/+ and Mmp3-/- mice exposed 
to LPS-induced lung injury compared to controls, with no effect of the genotype (Fig. 
3.2C). Male mice of both genotypes had also significantly higher lavage numbers of 
neutrophils following LPS-induced lung injury compared to Saline controls, with no effect 
stemming from lack of Mmp3 expression (Fig. 3.2D). 
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Figure 3.2 Experiment 1: Total (A, C) and differential (B, D) cell counts performed in 
lavage samples 18 hours post Saline or LPS intra-tracheal instillation. Total lavage cell 
numbers were determined in Mmp3+/+ and Mmp3-/- female (A) and male (C) mice. 
Following differential cell counts performed on cytospin slides, the total number of PMN 
neutrophils in lavage was obtained for female (B) and male (D) mice of both genotypes. 
Data are expressed as mean ± SEM; n=5-6 per group. *p<0.05 vs Saline control within the 
genotype. 
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Lavage inflammatory mediators 
To further characterize the role of MMP-3 in the pulmonary inflammatory response 
associated with ALI, the concentration of several cytokines and chemokines was measured 
in lung lavage. Data from Mmp3+/+ and Mmp3-/- female mice are shown in figure 3.3A to 
F, while results for male mice are shown in figure 3.4A to F. Overall, lavage concentrations 
of cytokines and chemokines did not differ between genotypes of Saline-instilled mice 
from both sexes (Figures 3.3 & 3.4). 
In female mice, LPS instillation led to significantly higher lavage concentrations of MIP-
2 in Mmp3+/+ mice compared to Saline controls. Significantly elevated lavage 
concentrations of IL-6, G-CSF, KC, MCP-1, and TNF-α were found in female, LPS-
instilled Mmp3+/+ and Mmp3-/- mice compared to the respective Saline controls (Fig. 3.3A-
F). Significantly lower lavage concentrations of IL-6, G-CSF, MIP-2, TNF-α, were 
observed in female, LPS-injured Mmp3-/- mice compared to the LPS-instilled Mmp3+/+ 
group, while differences in these experimental groups did not reach significance for the 
KC concentration (Fig. 3.3A-F). No differences were found for IL-10 (data not shown).  
The same array of inflammatory mediators was measured in the lavage of male mice and 
showed that LPS-induced injury caused significant increases in IL-6, G-CSF, KC, MIP-2, 
and TNF-α in Mmp3+/+ and Mmp3-/- mice compared to Saline mice, with no effect of the 
genotype (Fig. 3.4A-F) . No differences were detected in the lavage concentrations of 
MCP-1 (Fig. 3.4D) and IL-10 (data not shown). 
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Figure 3.3 Experiment 1: Cytokine and chemokine levels measured in lung lavage from 
Mmp3+/+ and Mmp3-/- female mice (A-F), 18 hours after LPS or saline instillation. Data 
are expressed as mean ± SEM; n=5-6 per group. *p<0.05 vs Saline control within the 
genotype; #p<0.05 vs Mmp3+/+ LPS group.  
IL-6= interleukin-6, G-CSF= granulocyte colony stimulating factor, KC= keratinocyte 
chemoattractant, MCP-1= monocyte chemotactic protein-1, MIP-2= macrophage 
inflammatory protein 2, and TNF-α= tumor necrosis factor alpha. 
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Figure 3.4 Experiment 1: Cytokine and chemokine levels measured in lung lavage from 
Mmp3+/+ and Mmp3-/- male mice (A-F), 18 hours after LPS or saline instillation. Data are 
expressed as mean ± SEM; n=5-6 per group. *p<0.05 vs Saline control within the genotype; 
#p<0.05 vs Mmp3+/+ LPS group.  
IL-6= interleukin-6, G-CSF= granulocyte colony stimulating factor, KC= keratinocyte 
chemoattractant, MCP-1= monocyte chemotactic protein-1, MIP-2= macrophage 
inflammatory protein 2, and TNF-α= tumor necrosis factor alpha. 
 
109 
 
3.3.2. Experiment 2: Acid-induced lung injury 
Lavage MMP-3 
The role of MMP-3 in ALI was also investigated in a model of acid-induced lung injury, 
in which female and male Mmp3+/+ and Mmp3-/- mice were exposed to an intra-tracheal 
instillation of HCl or Air, and sacrificed after a period of 4 hours. Similar to Experiment 1, 
the data have been separated by sex. 
Analysis of total lavage MMP-3 levels (Fig. 3.5) showed that acid injury led to significantly 
higher MMP-3 levels in the lavage of female and male Mmp3+/+ mice (Fig. 3.5A, B), 
compared to the respective Air controls. 
 
Figure 3.5 Experiment 2: MMP-3 levels measured in lavage samples from female (A) and 
male (B) Mmp3+/+ mice, 4 hours after intra-tracheal instillation of HCl or Air as a control. 
Data are expressed as mean ± SEM; n=5-6 per group. *p<0.05 vs Air control. 
 
Lavage protein 
The average lavage recovery volume from all animals was 2.9 ± 0.01 mL, with a significant 
difference only observed in male acid-instilled Mmp3-/- mice compared to Mmp3-/- Air 
control (2.99 ± 0.55 mL versus 2.81 ± 0.03 mL, respectively). Total protein content was 
measured in the lavage of female and male, Mmp3+/+ and Mmp3-/- mice (Table 3.2). When 
comparing Air-instilled mice within each sex, no differences in total protein content were 
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observed due to genotype. Overall, total protein content was significantly higher in mice 
exposed to acid-induced ALI compared to Air controls. These results were observed in 
both female and male mice, with no effect of the Mmp3 genotype (Table 3.2). 
 
 
Table 3.2 Experiment 2: Total protein content measured in lavage samples from female 
and male mice of both genotypes. Data are expressed as mean ± SEM; n=5-6 per group. 
*p<0.05 vs Air control within the genotype. 
 
Lavage inflammatory cells 
The total number of neutrophils in the lavage of Air-instilled mice did not differ between 
genotypes in both female (Fig. 3.6A) and male mice (Fig. 3.6B). The results in figure 3.6A 
showed a significantly higher number of neutrophils in female, acid-injured Mmp3+/+ mice 
compared to Air control. Nonetheless, the increase in lavage neutrophil numbers in female, 
acid-injured Mmp3-/- mice was not significant compared to the respective Air mice. Lower 
neutrophil abundance was observed in the lavage of female, acid-injured Mmp3-/- mice 
compared to Mmp3+/+ counterpart (Fig. 3.6A); however this difference did not reach 
significance.   
In male mice the increases in lavage neutrophils following acid injury were not statistically 
significant, and no effect stemmed from the difference in genotype (Fig. 3.6B). 
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Figure 3.6 Experiment 2: Total number of PMN neutrophils in lavage samples from 
female (A) and male (B) mice of both genotypes, 4 hours post air or acid instillation. Data 
are expressed as mean ± SEM; n=5-6 per group. *p<0.05 vs Air control. 
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Lavage inflammatory mediators 
Lavage concentrations of inflammatory mediators from Air-instilled mice of either sex did 
not show any difference due to genotype (Figures 3.7 & 3.8).  
In female mice (Fig. 3.7A-F), acid instillation led to significant increases in lavage IL-6, 
G-CSF, KC, MCP-1, MIP-2, and TNF-α in Mmp3+/+ mice compared to Mmp3+/+ Air mice; 
however in acid-injured Mmp3-/- mice such increases only reached significance for MIP-2 
and TNF-α (Fig 3.7A-F) compared to Air controls. Although non-significant, female acid-
injured Mmp3-/- mice appeared to have lower lavage concentrations of IL-6, G-CSF, KC, 
MCP-1, and had significantly lower concentrations of MIP-2 and TNF-α compred to acid-
instilled Mmp3+/+ mice (Fig 3.7A-F). IL-10 levels were increased following acid injury, 
with no effect of the genotype (data not shown). 
Analysis of the same inflammatory mediators in the lavage of male mice showed 
significantly higher concentrations of IL-6, MCP-1, and TNF-α in acid-instilled Mmp3+/+ 
mice compared to Air controls (Fig 3.8A-F). Significant increases in IL-6, MCP-1, G-CSF, 
KC, and MIP-2 were also observed in acid-injured Mmp3-/- mice compared to Air-instilled 
controls (Fig 3.8A-F). No differences were observed due to the Mmp3 genotype in male 
mice (Fig 3.8A-F) following acid injury; moreover, no effect of the genotype was noticed 
in IL-10 lavage levels (data not shown). 
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Figure 3.7 Experiment 2: Cytokine and chemokine levels in lavage samples from Mmp3+/+ 
and Mmp3-/- female mice (A-F), 4 hours following acid injury or air instillation. Data are 
expressed as mean ± SEM; n=5-6 per group. *p<0.05 vs Air control within the genotype; 
#p<0.05 vs Mmp3+/+ Acid group.  
IL-6= interleukin-6, G-CSF= granulocyte colony stimulating factor, KC= keratinocyte 
chemoattractant, MCP-1= monocyte chemotactic protein-1, MIP-2= macrophage 
inflammatory protein 2, and TNF-α= tumor necrosis factor alpha. 
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Figure 3.8 Experiment 2: Cytokine and chemokine levels in lavage samples from Mmp3+/+ 
and Mmp3-/- male mice (A-F), 4 hours following acid injury or air instillation. Data are 
expressed as mean ± SEM; n=5-6 per group. *p<0.05 vs Air control within the genotype; 
#p<0.05 vs Mmp3+/+ Acid group.  
IL-6= interleukin-6, G-CSF= granulocyte colony stimulating factor, KC= keratinocyte 
chemoattractant, MCP-1= monocyte chemotactic protein-1, MIP-2= macrophage 
inflammatory protein 2, and TNF-α= tumor necrosis factor alpha. 
 
115 
 
3.3.3. Experiment 3: In vitro stimulation of Mmp3+/+ and Mmp3-/- bone 
marrow-derived macrophages 
In order to investigate the observed MMP-3-related sex differences in pulmonary 
inflammation, inflammatory cells such as bone marrow-derived macrophages were isolated 
from female and male Mmp3+/+ and Mmp3-/- mice. Stimulation of these BMDMs with 
media only as a control or increasing doses of LPS (0.1µg/mL, 1µg/mL, 10µg/mL) led to 
step-wise increases in IL-6 in cell culture supernatant, with no significant differences 
related to the sex of the mice from which the cells were derived, or Mmp3 genotype (Fig. 
3.9A). 
A potential role of 17β-estradiol (E2) in the MMP-3 related differences in inflammatory 
response was addressed in BMDMs from female Mmp3+/+ and Mmp3-/- mice. The results 
in figure 3.8B showed that stimulation of BMDMs with 1µg/mL LPS caused increased 
release of IL-6 in cell culture supernatant, with no additional effect stemming from E2 co-
stimulation, and no differences associated with lack of Mmp3 expression (Fig. 3.9B).  
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Figure 3.9 Experiment 3: Stimulation of BMDMs isolated from Mmp3+/+ and Mmp3-/- 
mice. (A) BMDMs from female and male mice of both genotypes were stimulated with 
different doses of LPS (E. Coli 0111:B4) for 18 hours. IL-6 measurements in cell culture 
supernatant were normalized by values for female Mmp3+/+ BMDMs at 0.1µg/mL LPS. 
(B) BMDMs from female Mmp3+/+ and Mmp3-/- mice were stimulated for 18 hours with 
1µg/mL LPS alone, or LPS and three different doses of E2. IL-6 values in cell culture 
supernatant were normalized by values from female Mmp3+/+ BMDMs at 1µg/mL LPS. In 
both experiments, release of IL-6 in the control conditions was minimal and therefore not 
visible on the graphs. Data are expressed as mean ± SEM and representative of three 
experiments performed on three independent cell isolations. 
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3.4. Discussion  
The overall objective of this study was to investigate the role of MMP-3 in the 
inflammatory response associated with ALI. To this end, models of LPS- (experiment 1) 
and acid-induced lung injury (experiment 2) were utilized in mice lacking the expression 
of Mmp3, and in wild type controls. Consistent with previous experimental and clinical 
observations of increased MMPs expression during injury and inflammation [23, 24, 36], 
total MMP-3 levels were found elevated in the lavage of Mmp3+/+ mice following LPS or 
acid injury. In our models, lack of Mmp3 expression did not alter baseline responses in any 
of the measured outcomes. Following injury, lack of Mmp3 expression did not affect total 
protein in lavage and did not significantly alter the recruitment of neutrophils to the injured 
lung. Importantly, however, the release of cytokines and chemokines in response to the 
different injuries appeared to be consistently mitigated by the genetic ablation of Mmp3 in 
female mice, while male LPS- and acid-injured Mmp3-/- mice showed concentrations of 
pulmonary inflammatory mediators comparable to male injured Mmp3+/+ mice. Based on 
these data, it is concluded that MMP-3 plays a role in the pathogenesis of ALI by affecting 
pulmonary inflammation in a sex-dependent fashion. 
The role of MMP-3 in lung injury has been previously investigated in neutrophils-
dependent models of ALI, in which mice lacking Mmp3 expression demonstrated lower 
neutrophils infiltration and lower intra-pulmonary accumulation of proteinaceous edema 
in response to injury [32, 33]. Our data did not fully replicate those findings, due in part to 
differences in the nature of the injuries and their development, as well as potential technical 
limitations related to the retrieval of activated inflammatory cells and the sensitivity of the 
cell counting technique. In contrast to those previous studies, our experiments utilized 
mouse models that resembled two of the most common causes of lung injury in the patient 
population [5, 37]. Furthermore, in light of the association between lung cytokines/ 
chemokines and mortality in ALI [9, 38], the present research extended the previous 
observations on inflammation by analyzing the concentrations of several pulmonary 
inflammatory mediators. Overall, this study has investigated outcomes that are relevant in 
the pathogenesis of ALI, such as the development of pulmonary inflammation, and has 
explored sex differences in the response to lung insults. The current work, therefore, 
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provides an overall stronger clinical correlate about the role of MMP-3 in ALI than 
previously assessed.  
An unanticipated but interesting outcome of the current study were the MMP-3 related sex 
differences in the inflammatory response. Of interest, the sex of the mice previously 
utilized to investigate MMP-3 in ALI was not clearly reported in those studies [32, 33]. In 
a general sense, therefore, our findings underscore the upcoming policy changes announced 
by the National Institue of Health, which  recommend the inclusion of both sexes in 
experimental studies [39]. Such changes have been prompted by the observation that the 
almost exclusive use of male mice in research may have led to an under-estimation of sex-
driven differences in pathophysiology, and may have negatively impacted the translation 
of experimental findings into clinical practice [39]. Recent studies however started to 
demonstrate marked sex differences in the inflammatory response, with females mounting 
a better and more pronounced immune response to viral and bacterial infections, and being 
substantially more inclined to develop autoimmune disorders than males [40, 41]. In terms 
of pulmonary pathophysiology, sex differences have been observed in patients affected by 
cystic fibrosis (CF) or chronic obstructive pulmonary disease (COPD). Specifically, 
prepubertal female patients with CF have a higher mortality rate than peers of the opposite 
sex; females also exhibit higher prevalence and risk of hospitalization due to COPD than 
males [42, 43]. In patients with ALI, sex differences in mortality have not been observed 
[2]; however, a clinical study by Heffernan et al. indicated that, following traumatic injury, 
female patients are more likely to develop ALI [44].  
The underlying pathology leading to sex differences in the inflammatry responses in 
general may encompass gonadal hormones, sex chromosomes, and anatomical differences 
[45]. In the context of the current study, our in vivo models of ALI demonstrated that a lack 
of Mmp3 dampened the concentrations of lavage inflammatory mediators only in female 
mice, with no effect in males. These differences could be related to possible inflammatory 
dissimilarities inherent to the response of male/female Mmp3+/+ and Mmp3-/- mice, 
however there is also evidence of a potential relationship between sex hormones, 
specifically 17β-estradiol, and MMP-3. Different studies have in fact shown that exposure 
to E2 leads to up-regulation of Mmp3 expression by primary human osteoblasts, rat uterine 
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stromal cells, and human synovial fibroblasts [46–48]. These observations prompted our 
preliminary in vitro investigation into the sex-differences in the MMP-3-related 
inflammatory response, as shown in experiment 3. Based on the evidence of Mmp3 
expression in AM [20], and the role of AM in the progression and resolution of lung injury 
[49, 50], two experiments were performed on isolated BMDM to evaluate: i) inherent 
differences in the macrophage-driven inflammatory response of male/female Mmp3+/+ and 
Mmp3-/- mice; and ii) the possibility of an hormonal influence on the MMP-3 related sex 
differences. The data suggested that, with respect to IL-6 secretion, there were no inherent 
sex-related differences between female and male derived BMDM in response to LPS and/ 
or 17β-estradiol. 
Although those preliminary results suggest that BMDMs do not demonstrate sex 
differences, these experiments have some limitations and further research is required to 
elucidate the specific mechanisms by which the MMP-3-related sex-differences occur. For 
example, even though BMDMs provide a convenient, readily available and widely 
accepted in vitro model for alveolar macrophages [51, 52], some evidence suggests that 
AM may have properties and patterns of gene expression divergent from the ones 
characterizing BMDMs [53]. There is, of course, also the possibility that such MMP-3 
related sex differences do not involve the AM, but rather other cell populations within the 
lung (i.e. alveolar type II cells, fibroblasts) or more complex, systemic interactions. Future 
studies may address this aspect through broader in vitro analyses. Additionally, 
ovariectomized Mmp3+/+ and Mmp3-/- mice would be a useful model to determine whether 
estrogen- and, more generally speaking, sex hormones- have a role in MMP-3 related 
differences in the inflammatory response. 
As mentioned, the use of two different models of ALI is a strength of the study and an 
important aspect in the analysis of MMP-3 role. The rationale for such experimental 
approach resides, firstly, in the complex pathophysiology of ALI, which is associated with 
multiple and different initiating insults [5, 54]. Secondly, various models of ALI could help 
understand whether the role of MMP-3 differs depending on the lung insult. There is indeed 
some evidence that other MMPs, such as MMP-8 and -9, may have roles in ALI that vary 
depending on the nature of the initiating insult. For example, studies on Mmp9 knock-out 
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mice have shown that MMP-9 plays a pathogenic role during immunoglobulin G immune-
complex-induced lung injury [32], but appears to be protective from the development of 
ventilation-induced lung injury (VILI). Mice lacking Mmp9 expression were in fact more 
susceptible to the effects of injurious mechanical ventilation than wild type controls, 
presenting significant impairment in lung function and greater tissue damage [55]. 
Similarly, studies on MMP-8 have demonstrated that this protease has a protective role in 
models of LPS- and hyperoxia-induced lung injury while, on the other hand, it appears to 
favor the development of VILI [56, 57]. Overall, what emerges is the possibility that the 
role of matrix metalloproteinases in the pathogenesis of ALI may be dependent on the 
aetiology of lung injury. This evidence, combined with the multiplicity of causes leading 
to lung injury, undercores the necessity to perform ALI research through different injury 
models.  
In this regard, our ALI models are characterized at different time points (18 hours in 
experiment 1, 4 hours in experiment 2), and by different initiating insults with dissimilar 
features. Intra-tracheal instillation of LPS (experiment 1) has been described to cause the 
activation of specific intra-cellular inflammatory pathways, with patchy areas of 
neutrophils infiltration and limited epithelial damage [58], as demonstrated by the mild 
changes in lung permeability in LPS-injured mice observed in experiment 1 (table 3.1). 
Conversely, intra-tracheal instillation of HCl (experiment 2) resembles more of a chemical 
burn, and the subsequent lung injury was associated with damage of the alveolar 
epithelium, neutrophil infiltration, and extensive pulmonary edema as reflected by the 
significant changes in total protein content shown in table 3.2. In light of such differences, 
it is noteworthy that the involvement of MMP-3 in pulmonary inflammation in female mice 
was observed consistently in both models, thereby strengthening our conclusions. 
This important observation of reduced lavage cytokine and chemokine concentrations 
following lung injury in female Mmp3-/- mice has potential clinical relevance. The 
possibility of targeting MMP-3 to lower pulmonary levels of inflammation could improve 
outcomes of ALI. Within the pathophysiology of this disorder, the development of an 
overwhelming inflammatory response is indeed predictive of poor outcome [38, 59]. 
Experimental and clinical studies have shown that lung-derived inflammatory mediators 
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de-compartmentalized into the systemic circulation can affect the function of peripheral 
organs, with progression to multi organ failure and, eventually, death [10, 13, 60]. In this 
sense, a therapeutic approach capable of modulating the inflammation associated with lung 
injury would be an ideal treatment, and our study is a first step to assess whether MMP-3 
could be such key target. 
Aside from the aforementioned strengths, our study also has some weaknesses. For 
example, there may be intrinsic limitations related to the use of a mouse model that lacks 
Mmp3 expression as a result of gene disruption. Nonetheless, Mmp3-/- mice are fertile and 
viable, show no phenotypical alteration and appear to have normal lung function when 
unchallenged (chapter 4 and [20]), thereby representing a useful and valid tool for the study 
of MMP-3 in ALI.  
Additionally, the present study did not explore the potential mechanisms responsible for 
the decreased inflammation in female Mmp3-/- mice with ALI. It has been described that 
MMP-3 plays a role in inflammation through direct cleavage of specific inflammatory 
mediators, resulting in activation, potentiation of their activity, or inactivation of such 
molecules, and also through the generation of chemotactic gradients for neutrophils and 
macrophages [23]. Our data leave open the possibility that the effect of MMP-3 on ALI-
associated inflammation may result from direct or indirect proteolytic activity on a variety 
of inflammatory substrates. Importantly, however, new and non-enzymatic roles are 
emerging for MMP-3 in several disease processes [61, 62], thereby outlining a possibly 
more complex scenario than traditionally anticipated. More mechanistic insight about the 
role of MMP-3 in ALI could be gained in the future through the development of a 
catalytically inactive Mmp3 knock-in mouse or, when available, the administration of a 
highly selective MMP-3 inhibitor in models of lung injury. 
In conclusion, this study expanded the knowledge of ALI pathophysiology, addressing the 
role of MMP-3 in the context of two, clinically relevant models of lung injury. Our findings 
demonstrated a sex-dependent role for MMP-3 in the overwhelming lung inflammatory 
response associated with ALI, and highlighted the need for a better understanding of the 
disease processes in the search for future therapeutic approaches.  
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4.1. Introduction  
Acute lung injury (ALI) is a life threatening disorder initiated by a variety of insults to the 
lung, among which bacterial pneumonia is one of the most common [1]. No effective 
pharmacological therapy is currently available for the treatment of patients with ALI, and 
mortality is still extremely high at approximately 40% [2, 3]. The clinical criteria of ALI 
include an acute onset (within days) of respiratory failure due to pulmonary edema with no 
evidence of left ventricular failure, and hypoxemia, the latter of which is defined by the 
ratio of partial pressure of arterial oxygen over the fraction of inspired oxygen (PaO2 / FIO2) 
being lower than 300 mmHg [4].  
In order to develop novel therapies for ALI, better insight into the various complex 
pathophysiological alterations is required. One of the biggest challenges in this regard is 
the poor understanding of the relationship between the primary physiological alterations 
related to lung mechanics and oxygenation, as determined clinically as part of the definition 
of ALI, and the underlying inflammatory processes that appear to influence the mortality 
associated with the disease [1, 5–7]. The objective of this study was to utilize an 
experimental model, namely the Mmp3 deficient mouse, in which altered inflammatory 
processes in response to lung injury have been demonstrated [8, 9], and study the potential 
changes in lung mechanics and its associated changes to pulmonary surfactant in this 
setting.  
MMP-3 belongs to a family of zinc-dependent proteases that have important roles in innate 
immunity and inflammation [10, 11]. In the previous chapter, the role of this protease in 
lung injury was investigated in mice lacking Mmp3 expression (Mmp3-/-) and in wild type 
controls (Mmp3+/+) exposed to two different models of ALI (chapter 3, page 92). The 
results from both injury models highlighted a role for MMP-3 in the pathogenesis of this 
disorder. Specifically, the data showed a sex-dependent effect of MMP-3 on the pulmonary 
inflammatory response, with female Mmp3-/- mice having lower lavage concentrations of 
cytokines and chemokines following injury than female Mmp3+/+ controls  in both models 
of ALI.  
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Although these data constitute an important step towards a better understanding of the 
inflammatory response occurring in ALI, the role of MMP-3 in other aspects of the 
complex pathophysiology of ALI, such as lung mechanics, still needs to be investigated. It 
is clear that the hypoxemia defining ALI stems from many physiological and biochemical 
processes occurring within the lung, including decreased lung distensibility and increased 
work of breathing, which together with pulmonary edema, result in poor oxygenation [12]. 
The underlying mechanisms responsible for the alterations in the mechanical properties of 
the lung reside, to some extent, in the dysfunction of lung surfactant, an important 
substance that prevents alveolar collapse at the end of expiration [1, 13].  
Lung surfactant is essential to facilitate the work of breathing [13]. Surfactant is a lipid-
protein mixture secreted into the alveolar space, where it exists in two distinct structural 
forms: the functionally active large aggregates, and the inactive small aggregates, the latter 
existing as vesicular structures within the airspace [14]. Adsorbing at the air-liquid 
interface, the surfactant film reduces surface tension, thereby ensuring stability of the 
alveoli at low lung volumes and maintaining lung compliance [13]. The relationship 
between inactivation of lung surfactant and physiological alterations of lung function in 
ALI has been demonstrated in many different animal models of lung injury [12, 15–17]. In 
conjunction with in vitro analyses of surfactant samples isolated from injured lungs, these 
studies also have shown that the impairment in the surface tension reducing properties of 
the large aggregates, and the increased proportion of small aggregates relative to LA as 
injury progresses are associated with lower compliance and oxygenation [12, 15–17]. The 
mechanisms responsible for these surfactant alterations are several, and include functional 
inactivation by extravasated plasma proteins such as albumin and fibrinogen, and 
degradation and inactivation of surfactant components by proteases secreted by bacteria or 
inflammatory cells [18–20].  
Based on this information, it was hypothesized that MMP-3 contributes to alterations to 
lung mechanics and surfactant function during ALI. This hypothesis was tested by 
exposing Mmp3+/+ and Mmp3-/- mice of both sexes to an 18-hour model of 
lipopolysaccharide (LPS)-induced lung injury, followed by histological assessment of lung 
injury, measurement of pulmonary mechanics, and in vitro analyses of lung surfactant. 
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4.2. Methods  
4.2.1. Animal procedures and experimental design 
Mice lacking the expression of Mmp3 (Mmp3-/-) were originally generated as previously 
described by Mudgett JS et al [21]. Two breeding pairs were kindly donated to our 
laboratory by Dr. G.P. Downey (National Jewish Hospital, Denver, Colorado), and utilized 
to obtain a pathogen-free colony via back-crossing with Mmp3 wild type mice (Mmp3+/+) 
on a C57BL/6 background. All mice were housed in an animal research facility, with ad 
libitum access to food and water and daily exposed to a 12 hours light/dark cycle. All 
procedures were reviewed and approved by the Animal Use Subcommittee at Western 
University (protocol #: 2010-272). 
A total of 39 Mmp3+/+ and Mmp3-/- mice (17.9 ± 0.4 weeks old) of both sexes were exposed 
to an 18-hour model of LPS-induced lung injury previously described (chapter 3) and 
utilized for the analyses of lung mechanics and histology. Surfactant analyses were 
performed on samples isolated from a cohort of mice (14.5 ± 0.4 weeks old) utilized in 
chapter 3 (details in section 3.2) and exposed to the same injury model.  
4.2.2. Lipopolysaccharide-induced lung injury 
Female and male Mmp3+/+ and Mmp3-/- mice were randomized to receive an intratracheal 
(i.t.) instillation of LPS (from E.Coli, 0111:B4, 20 µg/mouse; Sigma, St. Louis, Mo., USA), 
or saline (0.15M NaCl solution) as a control. Based on the evidence from our previous 
study (chapter 3), data from female and male mice were analyzed separately leading, for 
each sex, to the following experimental groups: i) Mmp3+/+ Saline, ii) Mmp3+/+ LPS, iii) 
Mmp3-/- Saline, iv) Mmp3-/- LPS.  
For a more detailed description of the instillation and other experimental procedures related 
to this model, please refer to chapter 3, section 3.2, page 95.  
4.2.3. Analysis of lung mechanics 
Eighteen hours after LPS instillation, mice received an intraperitoneal injection of sodium 
pentobarbital (110 mg/kg; Lundbeck, Valby, Denmark) with a euthanasing dose. When the 
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appropriate depth of anesthesia was reached, mice were placed in a supine position, and 
the lower abdomen was exposed through a small midline incision. The inferior vena cava 
was identified, and 50 µL of heparin (Sandoz, Boucherville, QC, Canada) were injected 
intravenously over a 1 minute-period, followed by mice exsanguination. A tracheostomy 
was subsequently performed, and an endotracheal tube was secured in the trachea. Mice 
were then returned to a prone position, and connected to a FlexiVent rodent ventilator 
(Scireq, Montreal, Quebec, Canada) for ex vivo measurements of lung function, via 
Flexiware software controlled maneuvers. Immediately after connecting the endotracheal 
tube to the FlexiVent ventilator, mice were exposed to 2 minutes of ex vivo mechanical 
ventilation (Vt = 10 mL/kg, RR =150 breaths/min, PEEP = 0 cmH2O), before being 
exposed to 4 different maneuvers. These software-controlled procedures were performed 
with 10 seconds intervals of ex vivo ventilation. In order to standardize volume history, the 
first maneuver performed was a deep inflation of the lungs from PEEP value to a maximal 
pressure of 30 cmH2O. This maneuver, representing the total lung capacity (TLC), also 
allowed for the determination of the inspiratory capacity (IC). A single frequency (150 bpm 
or 2.5Hz) forced oscillation technique (FOT) was subsequently performed, in which a 
sinusoidal waveform was over imposed on the mouse lungs. The signal output of this 
analysis can be implemented onto a single compartment model using linear regression, 
leading to determination of compliance (Crs), elastance (Ers), and resistance (Rrs) of the 
whole respiratory system. The third maneuver consisted of the application of a broad-band 
FOT (over a range of mutually prime frequencies); the resulting input impedance of the 
respiratory system was fit onto the constant phase model to determine values of airway 
resistance (RN), tissue damping (G), and tissue elastance (H). Lastly, software-controlled 
pressure-volume (PV) curves were performed via step-wise increases in pressure, in order 
to calculate quasi-static lung compliance (Cst) and elastance (Est). An overview of 
maneuvers and outcomes of interest in this study is provided in Table 4.1. Once all 
measurements had been performed, ex vivo ventilation was delivered for an additional 10 
seconds, before disconnecting the endotracheal tube from the ventilator and proceeding 
with lung isolation for histological analysis. 
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Table 4.1: Summary of the maneuvers and outcomes of respiratory mechanics relevant in 
this thesis work. TLC, total lung capacity; FOT, forced oscillation technique; PV curve, 
pressure-volume curve. 
4.2.4. Histology  
Following measurements of lung mechanics, the lungs and heart were isolated en block. 
Briefly, the diaphragm was cut and a midline incision was performed to open the rib cage 
and expose the lungs. Lungs, heart, and trachea with the previously placed endotracheal 
tube intact were carefully removed, connected to a manometer and air inflated to a pressure 
of 15 cmH2O. A tight knot was then performed to occlude the trachea, the endotracheal 
tube removed, and the isolated heart-lungs block immersed in a fixative solution of 4% 
paraformaldehyde for at least 24 hours. Fixed lungs were rinsed twice, for 20 minutes and 
under gentle rocking, with phosphate buffered saline, before being placed in increasingly 
higher concentrations of ethanol (v/v %; 30% then 50% ethanol for 20 minutes each, at 
room temperature with gentle rocking), and kept in 70% ethanol at 4˚C until further 
processing, kindly performed by Dr. Chris Howlett (Dept. of Pathology and Laboratory 
Medicine, Western University, Canada). Once wax embedded, lungs were sectioned into 
slices and stained with hematoxylin and eosin (H&E) stain. The development of lung injury 
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was subsequently assessed through analysis and scoring of the lung tissue slides by a 
pathologist blinded to the experimental conditions.  
The scoring system applied to the histological sections for the semi-quantitative assessment 
of lung injury is shown in Table 4.2, while figure 4.1 (A-D) provides representative 
pictures, from lung sections used in this experiment, exemplifying the degree of lung injury 
for each point of the scoring system. The lowest score assigned was 0, representing a 
normal histological section with no significant inflammatory or structural alterations (Fig. 
4.1A), proceeding up to 3, which was assigned to lung sections with substantial neutrophil 
infiltrate and structural damage (Fig. 4.1D). 
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Table 4.2: Scoring system utilized for the assessment of lung injury on H&E stained lung 
sections. 
 
Figure 4.1: Representative images of the histology score utilized for the analyses of lung 
sections isolated from female and male Mmp3+/+ and Mmp3-/- mice, 18 hours post intra-
tracheal instillation of LPS or saline. (A) Score 0, (B) score 1, (C) score 2, (D) score 3. 
Slides stained with hematoxylin and eosin; magnification, 40x. Scale bar = 100µm shown 
in the bottom right corner of panel D. 
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4.2.5. Lung lavage isolation and surfactant analysis 
Lung lavage samples were isolated from the cohort of mice described in chapter 3. 
Experimental details about lung lavage isolation are provided in chapter 3, section 3.2.4, 
page 97. Following centrifugation of whole lung lavage at 380 g at 4˚C for 10 min., the 
supernatant was collected and termed total surfactant (TS). Part of TS was aliquoted and 
utilized for the measurements of inflammatory mediators and protein content described in 
chapter 3; 1 mL of TS was centrifuged at 40,000 g at 4˚C for 15 min. to separate the heavier 
large aggregate (LA) sub-fraction (pellet) from the small aggregate (SA) sub-fraction 
(supernatant). The LA pellet was resuspended in 0.3 mL of 0.9% NaCl. The remaining 
volume of TS was utilized for analysis of total surfactant pool sizes. TS, LA, and SA were 
stored frozen at -80˚C until further analysis. The phospholipid content of TS, LA, and SA 
was determined via phosphorous assay on the lipid component extracted by the Bligh and 
Dyer method, as previously described [22, 23], and corrected by body weight. The percent 
LA indicates the percent proportion of LA over the sum of LA and SA. 
4.2.6. Biophysical analysis of surfactant activity 
Individual crude LA samples were centrifuged at 21,000 g at 4˚C for 15 minutes, and the 
resulting pellets were resuspended in a buffer solution (2.5 mM HEPES, 1.5 mM CaCl2, 
pH 7.2) to a final phospholipid concentration of 1 mg/mL. For each of these LA samples, 
9 to 10 µL were utilized for the analysis of their surface tension reducing properties through 
a computer controlled constrained sessile drop surfactometer, as previously described [24]. 
This system is composed of a light source (Advanced Illuminator CS410, Rochester, VT, 
USA) and a microscope connected to a camera (1.3 Megapixel CMOS monochrome 
camera), all directed at a pedestal on which LA samples are deposited, thereby forming a 
drop. The pedestal, which has the top and lateral sides arranged in an approximately 60˚ 
angle, has a sharp edge that prevents the drop from spilling over. It is also provided with a 
central hole, which is connected to a motor-driven syringe controlled by a computer 
software and utilized for the cyclic compression and expansion of the surfactant drop. 
Twenty-five to thirty cycles were performed per minute, at 37˚C, for each LA sample. All 
processes of image recording and image analysis were automated. Images were recorded 
at 10 frames per second throughout the duration of the thirty cycles. All images were 
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sequentially analyzed via the axisymmetric drop shape analysis, providing values of 
surface tension and surface area for each picture during the complete dynamic cycles. 
Values of minimum surface tension at cycles 1-10, 15, 20, and 25 were subsequently 
analyzed. The percent surface area compression necessary to reach minimum surface 
tension at cycle 10 was also measured for each drop. 
4.2.7. Statistical analysis 
All data are expressed as mean ± standard error of the mean (SEM). The GraphPad 
statistical software (La Jolla, CA, USA) was used to perform statistical analyses. A two-
way ANOVA (variables: genotype and treatment) was utilized to analyze the data, 
followed by a one-way ANOVA with a Tukey’s post-hoc test. P<0.05 was considered 
statistically significant.  
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4.3. Results  
Lung histology 
Representative pictures of lung histology with a summary of the histological score are 
shown in Figure 4.2 for female mice, and Figure 4.3 for male mice. Overall, no differences 
were found in the lung histology of Saline-instilled female (Fig. 4.2A, C, E) or male mice 
(Fig. 4.3A, C, E), indicating that the genotype itself had no effect on the histological 
indications of lung injury. 
Based on the scoring system outlined in table 4.2, the analysis of lung histological sections 
from female Mmp3+/+ and Mmp3-/- mice showed a significantly higher histology score in 
LPS-instilled mice compared to their respective Saline controls (Fig. 4.2E), with increased 
cellularity and parenchymal damage following LPS injury (Fig. 4.2B, D) than after saline 
instillation (Fig. 4.2A, C). No effect of the genotype was observed (Fig. 4.2 A-E).  
In male mice, the increases in the histology score of LPS-injured mice reached significance 
only in the Mmp3-/- group compared to Saline controls (Fig. 4.3E). The extent of lung 
injury in LPS-instilled male Mmp3+/+ and Mmp3-/- mice was mild to moderate, with 
peribronchial infiltrates, thickening of the septa and/or patchy areas of more pronounced 
inflammation following injury (Fig. 4.3B, D) compared to saline instillation (Fig. 4.3 A, 
C). No effect of the genotype was observed (Fig. 4.3E). 
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Figure 4.2: Hematoxylin-eosin stained pictures representative of lung sections from 
female Mmp3+/+ (A, B) and Mmp3-/- (C, D) mice, 18 hours after saline (A, C) or LPS (B, 
D) instillation. Magnification, 100x. (E) Quantitative histological assessment of lung 
injury. Analyses were performed on lung sections from female Mmp3+/+ and Mmp3-/- mice, 
according to the scoring system described above. Data are expressed as mean ± SEM; n=4-
6 per group; *p<0.05 vs Saline control. Scale bar = 100µm shown in the bottom right corner 
of panel D. 
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Figure 4.3: Representative hematoxylin-eosin stained pictures of lung sections from male 
Mmp3+/+ (A, B) and Mmp3-/- (C, D) mice, 18 hours after saline (A, C) or LPS (B, D) 
instillation. Magnification, 100x. (E) Quantitative histological assessment of lung injury. 
Analyses were performed on lung sections from male Mmp3+/+ and Mmp3-/- mice, 
according to the scoring system described above. Data are expressed as mean ± SEM; n=4-
5 per group; *p<0.05 vs Saline control. Scale bar = 100µm shown in the bottom right corner 
of panel D. 
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Lung mechanics 
Results from the assessment of respiratory mechanics in female Mmp3+/+ and Mmp3-/- mice 
are shown in figure 4.4A-I. No differences due to genotype were observed in Saline 
controls, for any of the outcomes. LPS-instilled mice showed a reduction in inspiratory 
capacity (IC; Fig. 4.4G) that reached statistical significance only in the LPS-injured  
Mmp3-/- group, compared to the Saline controls. Analysis of dynamic compliance (Crs), 
dynamic elastance (Ers), and dynamic resistance (Rrs) for the whole respiratory system 
demonstrated alterations of these parameters only in   Mmp3-/- mice following LPS injury. 
Specifically, Crs was significantly reduced, while Ers and Rrs were significantly increased 
in female LPS-injured Mmp3-/- mice compared to Saline (Fig. 4.4A, B, C respectively).  
LPS-induced lung injury also led to a significant reduction in quasi-static compliance (Cst; 
Fig. 4.4D) and a significant increase in quasi-static elastance (Est; Fig. 4.4E) in female 
Mmp3+/+ and Mmp3-/- mice, compared to Saline-instilled controls. Lastly, no changes were 
observed overall for measurements of central airway resistance (RN; Fig. 4.4F), while LPS 
instillation led to significantly higher tissue resistance (tissue damping, G; Fig 4.4H) and 
elastance (H; Fig. 4.4I) only in female Mmp3-/- mice compared to Saline controls. No 
statistical differences due to genotype were observed in LPS-instilled female mice, for any 
of the measurements performed (Fig. 4.4A-I). 
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Figure 4.4: Analysis of respiratory mechanics in female Mmp3+/+ and Mmp3-/- mice, at 18 
hours post LPS or saline instillation. (A) Lung compliance (Crs), (B) elastance (Ers), and 
(C) resistance (Rrs) of the whole respiratory system were obtained through a single 
frequency forced oscillation technique (FOT). (D) Quasi-static compliance (Cst) and (E) 
elastance (Est) resulted from P-V curves performed via step-wise increases in pressure. 
Broadband FOT was utilized to obtain values of (F) central airway resistance (RN), (H) 
tissue damping (G), and (I) tissue elastance (H). (G) IC, inspiratory capacity. Data are 
expressed as mean ± SEM; n=4-6 per group; *p<0.05 vs Saline control. 
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Respiratory mechanics were also analyzed in male Mmp3+/+ and Mmp3-/- mice (Fig. 4.5A-
I). No differences were present due to genotype between Saline controls. Following LPS 
instillation, no significant changes were observed in inspiratory capacity (Fig. 4.5G), 
dynamic compliance, elastance, and resistance of the respiratory system (Fig. 4.5A, B, and 
C respectively) compared to Saline-instilled mice in both genotypes. A decrease in quasi-
static compliance and an increase in quasi-static elastance was observed in male, LPS-
instilled Mmp3+/+ and Mmp3-/- mice compared to Saline controls (Fig. 4.5D, E); however, 
these differences did not reach statistical significance. Additionally, measurements of 
airway resistance (Fig. 4.5F), tissue damping indicative of tissue resistance (Fig. 4.5H), 
and tissue elastance (Fig. 4.5I) did not show any significant change due to LPS injury. 
Lastly, no effect of the genotype was observed for any of the performed measurements in 
male, LPS-injured mice (Fig. 4.5A-I). 
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Figure 4.5: Analysis of respiratory mechanics in male Mmp3+/+ and Mmp3-/- mice, at 18 
hours post LPS or saline instillation. (A) Lung compliance (Crs), (B) elastance (Ers), and 
(C) resistance (Rrs) of the whole respiratory system were obtained through a single 
frequency forced oscillation technique (FOT). (D) Quasi-static compliance (Cst) and (E) 
elastance (Est) resulted from P-V curves performed via step-wise increases in pressure. 
Broadband FOT was utilized to obtain values of (F) central airway resistance (RN), (H) 
tissue damping (G), and (I) tissue elastance (H). (G) IC, inspiratory capacity. Data are 
expressed as mean ± SEM; n=4-6 per group; *p<0.05 vs Saline control. 
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Surfactant analysis and biophysical activity 
The analysis of surfactant sub-fractions is shown in figure 4.6A-D for both sexes. Overall, 
there were no differences in surfactant pool sizes between Saline instilled mice as a result 
of the different genotype. This was observed in both female (Fig. 4.6A, B) and male mice 
(Fig. 4.6C, D). 
In female mice, no differences were found in TS and SA pool sizes following LPS injury, 
or as a result of lacking Mmp3 expression (Fig. 4.6A). The amount of LA (Fig. 4.6A) and 
the percent LA (Fig. 4.6B) were significantly higher in female, LPS-injured Mmp3+/+ mice 
compared to Saline control, while no increases in the LA sub-fraction (Fig. 4.6A) and 
percent LA (Fig. 4.6B) were found in female, Mmp3-/- mice exposed to LPS injury. 
Furthermore, female LPS-instilled Mmp3-/- mice had significantly lower LA amounts than 
LPS-injured Mmp3+/+ mice (Fig. 4.6A). 
In male mice, no significant differences were observed in the amounts of TS, LA, or SA 
between LPS-injured and Saline-instilled mice; moreover, there was no effect of the 
genotype on male surfactant pool sizes (Fig. 4.6C). In line with these observations, there 
were no significant changes in the percent LA retrieved following LPS injury or in mice 
lacking Mmp3 (Fig. 4.6D). 
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Figure 4.6: Surfactant pool sizes (A, C) and percent large aggregates (B, D) measured in 
female (A, B) and male (C, D) Mmp3+/+ and Mmp3-/- mice, 18 hours after LPS or saline 
instillation. (A, C) Total surfactant (TS), large aggregate (LA), and small aggregate (SA) 
sub-fractions were measured in isolated lung lavage samples. The data represent the 
amount of phospholipids normalized by body weight. Within each sub-fraction, *p<0.05 
vs Saline control of the same genotype; #p<0.05 vs Mmp3+/+ LPS. (B, D) The data 
represent the proportion of LA over the sum of LA and SA. *p<0.05 vs Saline control of 
the same genotype. Data are expressed as mean ± SEM; n=5-6 in each group. 
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The biophysical activity of LA samples was evaluated using a constrained sessile drop 
surfactometer. The minimum surface tension achieved by LA samples during repeated 
cycles of compression-expansion is shown in Table 4.3. Minimum surface tension of LA 
samples from Saline instilled mice did not differ between genotypes in both female and 
male mice. 
No differences were found in the surface activity of LA samples from female, LPS-injured 
mice compared to Saline controls at cycles 1, 5, and 10 of dynamic compression-expansion 
(Table 4.3). Furthermore, no effect of the genotype on LA biophysical activity was 
observed for any of the cycles (Table 4.3). 
LA samples from male, LPS-injured mice also reached values of minimum surface tension 
that were not significantly different from Saline-instilled controls (Table 4.3); moreover, 
lack of Mmp3 expression did not affect the surface activity of LA in male mice at cycles 
1, 5, and 10 (Table 4.3). 
The surface tension reducing properties of LA samples were further assessed through 
measurements of the percent area compression necessary to achieve minimum surface 
tension at a given cycle of compression-expansion (cycle 10). The data in Table 4.4 show 
no significant differences in percent area compression at baseline between Saline-instilled 
mice, and in LPS-instilled mice of either sex compared to the respective Saline-instilled 
controls. Additionally, no effect of the genotype was observed in LPS-instilled female or 
male mice (Table 4.4). 
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Table 4.3: Surface activity of LA samples at cycle #1, #5, and #10 of dynamic 
compression-expansion cycles, performed via a constrained sessile drop surfactometer. 
Data are expressed as mean ± SEM; n=5-6 in each group. 
 
 
Table 4.4: Percent area compression at cycle #10 of dynamic compression-expansion, 
needed to achieve minimum surface tension. Measurements performed via a constrained 
sessile drop surfactometer. Data are expressed as mean ± SEM; n=5-6 in each group. 
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4.4. Discussion  
The objective of the present study was to investigate whether MMP-3, previously shown 
to modulate the pulmonary inflammatory response in models of lung injury (Chapter 3), 
could affect the changes in histology, respiratory mechanics, and surfactant function 
associated with ALI. Analysis of lung histological sections from female and male Mmp3+/+ 
and Mmp3-/- mice demonstrated alterations in the alveolar architecture and increased 
neutrophil infiltration in response to LPS instillation, which was consistent with previous 
observations of this injury model. Notably, lungs from female mice exposed to LPS were 
less compliant and had greater elastic recoil compared to Saline controls, while such 
changes in respiratory mechanics were less prominent and not statistically significant in 
male mice given LPS versus control. Lastly, isolated surfactant samples retained good 
biophysical properties across all experimental groups. No effect of Mmp3 ablation was 
observed for the majority of the measured outcomes following LPS instillation, with the 
exception of LA pool size in female, LPS-injured mice. Furthermore, no differences due 
to genotype were observed at baseline between Saline-instilled mice in both sexes. Based 
on these data, and on the observations from our previous study (chapter 3), it was concluded 
that although MMP-3 impacts inflammation in LPS-induced injury in female mice, this 
protease does not impact pulmonary mechanics and surfactant function associated with 
lung injury.  
The contribution of MMP-3 to lung injury has been previously demonstrated in models of 
ALI initiated by intra-tracheal instillation of immunoglobulin G, or instillation of the 
chemokine MIP-2 [8, 9]. In those models, lack of Mmp3 mitigated the development of 
injury mainly through reduced recruitment of inflammatory neutrophils to the lung [8, 9]. 
In our previous study (chapter 3), lack of Mmp3, while not affecting lavage neutrophil 
numbers, led to decreased inflammatory mediators in the lavage of female mice exposed 
to LPS-induced ALI. This same injury model has been utilized in the current work to 
investigate the interplay between pulmonary inflammation, surfactant, and lung mechanics 
in order to gain a better understanding of ALI pathophysiology. In ALI, this relationship 
appears to be very complex with various experimental evidence supporting an important 
role for surfactant in modulating pulmonary inflammation, but with other evidence 
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supporting a marked effect of inflammation on surfactant composition and function and, 
consequently, lung mechanics. Furthermore, in some other studies, inflammation and 
surfactant alterations appear to occur independently.   
For example, modalities of mechanical ventilation (MV), the main supportive therapy in 
ALI, that are considered to be injurious for the lung can lead to surfactant impairment and 
decreased compliance, and have been associated with increased pulmonary inflammation 
[12, 25, 26]. Interestingly, maintaining an active surfactant system in this scenario has been 
shown to reduce pulmonary inflammation [27]. Lung surfactant, comprised of 
phospholipids and surfactant associated proteins (surfactant proteins A-D), also has 
important immuno-modulatory properties within the alveolar space [13, 28]. Specifically, 
surfactant protein C (SP-C) has been recently shown to have an anti-inflammatory role in 
a model of chronic LPS exposure, as mice lacking SP-C expression had more intense lung 
inflammation compared to wild type [29]. Additionally, numerous evidence support the 
role of SP-A and SP-D in host defense and inflammation. SP-A has been shown to 
modulate levels of inflammatory mediators such as TNF-α and, interestingly, mice lacking 
the expression of SP-A have higher lavage concentrations of IL-6 and TNF-α following 
lung injury [28, 30]. Thus, there is strong evidence supporting the concept that pulmonary 
surfactant can impact inflammatory responses. 
Conversely, and more relevant to the current study, inflammatory mediators released in the 
alveolar space during ALI can affect lung surfactant metabolism, and inhibit the expression 
of surfactant proteins such as SP-A and SP-B with potential consequences on surfactant 
biophysical function [31–33]. Moreover, proteases from inflammatory cells or bacteria 
present within the alveolar space have been shown to degrade surfactant associated 
proteins, thereby altering aggregate conversion and increasing surfactant minimum surface 
tension values [19, 20, 34]. Whether any of the four surfactant associated proteins could be 
a potential substrate for MMP-3 is currently not known. In our experiment, the lower 
concentration of inflammatory mediators released in the alveolar space of female Mmp3-/- 
mice after LPS injury (Chapter 3) did not appear to have a major impact on surfactant 
function and lung mechanics when compared to Mmp3+/+ mice. These data, in part, 
reproduced the findings by Nakamura et al. which demonstrated that mice lacking the 
153 
 
expression of Il6, a major cytokine and marker of ALI, had changes in surfactant and lung 
function following lung injury that were not different from the ones affecting injured, wild 
type animals [35]. Yamashita et al. also showed that, in mice with aberrant inflammatory 
processes due to absence of Apolipoprotein E, the elevated lavage concentrations of IL-6, 
KC, MCP-1, and TNF-α after lung injury did not correlate with physiological outcomes 
measured in the study [36]. Indeed, surfactant pool sizes, percent LA, oxygenation, and 
lung distensibility were not different from the ones measured in control injured mice, which 
experienced only minor inflammatory changes [36]. Together, these data underscore the 
complex nature of the relationship between inflammation and surfactant. It is likely that 
the specific cause of lung inflammation, the different cell types involved, as well as the 
nature and concentrations of the inflammatory mediators have all an impact on these 
processes; future studies are required to clarify these aspects. 
Although no major effect of genotype was observed in the present study, the biochemical 
and functional changes to lung surfactant in this model are of general interest to our 
understanding of ALI. In our analysis of surfactant pool sizes, a significant increase in the 
active LA sub-fraction and percent LA was observed in female, LPS-instilled Mmp3+/+ 
compared to Mmp3+/+ Saline control, while female LPS-instilled Mmp3-/- mice maintained 
LA pool sizes comparable to Mmp3-/- Saline control. Similar observations were reported 
by Nakamura et al. and Malloy et al. in spontaneously breathing animals exposed to a cecal 
ligation and perforation model of sepsis-induced ALI [16, 26, 37, 38]. In these studies, no 
differences were found in LA pool sizes between control and septic animals; moreover, as 
reported by Malloy and colleagues, the percent LA relative to TS was significantly 
increased in spontaneously breathing septic mice compared to uninjured controls [16]. 
Interestingly, the application of mechanical ventilation to septic lungs led to alterations in 
surfactant aggregates more reflective of the surfactant alterations observed in ALI patients 
all of whom are, in fact, mechanically ventilated [16, 39]. Such changes in aggregates 
consist in a relative decrease in LA and increase in SA. This has been shown to result from 
the increased conversion of LA into SA during lung injury, process that is influenced by 
changes in tidal volumes and consequent changes in the alveolar surface area [40]. In other 
words, the larger tidal volumes delivered with mechanical ventilation, compared to 
spontaneous breathing, cause larger surface area changes and greater LA to SA conversion, 
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leading to decreased percent LA. Even though tidal volumes were not measured in the 
current work, it could be speculated that the tidal volume in female mice was reduced 
following LPS injury, thereby preserving LA pool sizes.  
Importantly, preservation of the LA pool sizes may have partially overcome inhibition of 
surfactant by leaked serum proteins, or released proteases. In this sense, our biophysical 
surfactant analyses demonstrated that LA samples from mice of both sexes and genotypes 
retained good surface tension reducing properties, even following LPS injury. These 
findings seemingly conflict with the notion that decreased compliance in ALI results from 
impaired surfactant function; however, regional variability in LPS-induced lung injury 
should also be taken into consideration when interpreting these data. As surfactant is 
routinely isolated through lavage of the whole lung, impaired material originating from the 
more injured areas may ultimately combine with surfactant from functional, non-injured 
alveoli. It becomes more difficult, therefore, to detect surfactant impairments, when 
present, under all the aforementioned circumstances. 
Despite such limitations, the biophysical analysis of surfactant constitutes an innovative 
aspect of this study. This is indeed the first time that the surface activity of surfactant 
samples from Mmp3-/- mice has been analyzed, both at baseline (Saline group) and post-
lung injury (LPS group). Moreover, accurate and sensitive determination of surface tension 
was obtained through the use of a constrained sessile drop surfactometer, a new technology 
that also provides rigorous control of experimental settings such as temperature and 
humidity of the chamber where the sessile drop is contained [24, 41]. Most importantly, 
the constrained sessile drop surfactometer requires the use of small sample volumes, 
thereby overcoming the necessity of sample-pooling that is typical of traditional systems 
of surfactant analysis (see chapter 2, captive bubble surfactometer) and allowing 
measurements of surface tension in individual mouse LA samples. 
In addition to analyzing surfactant, one of the goals of this study was to expand the 
knowledge of the respiratory mechanics in Mmp3-/- mice, both at baseline and following 
lung injury. Previous measurements of lung compliance were performed in Mmp3-/- mice 
following bleomycin-induced fibrosis [42]. That study showed greater compliance in 
bleomycin-instilled Mmp3-/- mice compared to Mmp3+/+ controls, and highlighted a role 
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for MMP-3 in the development of lung fibrosis following acute inflammation [42]. Aside 
from this particular study, the information related to the changes in respiratory mechanics 
associated with lung injury in Mmp3-/- mice is very limited. Our investigation addressed 
this knowledge gap through the use of the FlexiVent mechanical ventilator, a system that 
provides reliable and reproducible measurements of lung mechanics, task that is otherwise 
difficult to accurately perform in spontaneously breathing mice [43, 44]. In general, it was 
observed that lack of Mmp3 did not affect respiratory mechanics at baseline or following 
injury in both sexes. Measurements of quasi-static compliance and quasi-static elastance 
in our study illustrated changes in female, LPS instilled mice that were consistent with 
mechanical alterations typical of ALI. Additionally, a significant decrease in dynamic 
compliance (Crs), and significant increases in elastance and resistance of the whole 
respiratory system (Ers, Rrs) were only observed in female, LPS injured Mmp3-/- mice 
compared to Saline Mmp3-/- controls, but not within the Mmp3+/+ groups. These 
mechanical changes were possibly related to modifications in the lung parenchyma, as 
suggested by the increases in tissue resistance (G) and tissue elastance (H), which are 
representative of the dissipative and elastic properties of the lung tissue, but no significant 
changes in the resistance of the central airways (RN). It could be speculated that such 
changes observed in female, LPS injured Mmp3-/- mice compared to Saline Mmp3-/- 
controls stemmed from a slower repair process in the Mmp3-/- mice. It has been previously 
shown that early contraction of dermal wounds occurred more slowly in vivo in Mmp3-/- 
mice compared to Mmp3+/+ mice, and that Mmp3-/- lung fibroblasts demonstrated impaired 
contraction in vitro [45, 46]. Nevertheless, Mmp3-/- mice exposed to bleomycin injury were 
protected from developing pulmonary fibrosis, suggesting that the overall repair process is 
ultimately functional in these mice [42].  
Lastly, while LPS-induced lung injury appeared to elicit significant responses in female 
mice for most of the measured outcomes, instillation of LPS in male mice did not always 
yield significant changes compared to their respective Saline controls, as particularly 
evident in the analyses of respiratory mechanics and surfactant pool sizes. These findings 
are consistent with observations noted in chapter 3, in which the inflammatory response of 
male mice exposed to the same 18 hour model of LPS-induced lung injury appeared to be 
of lower magnitude than the one elicited in Mmp3+/+  female mice. A formal statistical 
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comparison between male and female mice, however, has not been performed in either 
studies, and further investigations are required to appropriately address the issue of sex 
differences in the response to injury. 
In conclusion, this study investigated the interplay between pulmonary inflammation, lung 
mechanics and surfactant function in a mouse model of ALI, specifically expanding our 
knowledge of the role of MMP-3 in the modulation of physiological outcomes of ALI. The 
results from the current study suggest that MMP-3 did not appear to participate in such 
modulation, and that the decrease in lavage inflammatory mediators (i.e. IL-6, G-CSF, 
MIP-2, and TNF-α) previously observed in female Mmp3-/- mice with lung injury (Chapter 
3) did not correlate with superior lung mechanics and surfactant function following LPS-
induced ALI. The specific interplay between alveolar cytokines and chemokines, lung 
surfactant and pulmonary function requires further investigation. Given the correlation 
between soluble inflammatory mediators and outcomes of ALI, a better understanding of 
these relationships could ultimately result in more effective treatments and an improved 
mortality. 
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CHAPTER 5:  
General discussion and future directions 
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5.1. Summary and discussion of major findings 
The overall objective of this work was to advance the knowledge of ALI, a pulmonary 
inflammatory disorder associated with a complex pathophysiology and lacking any 
effective pharmacological therapy [1, 2]. One of the major challenges facing the 
development of treatments for this disease is to effectively compromise between supporting 
the impaired lung function through mechanical ventilation (MV) on one hand, and limiting 
the propagation of lung inflammation, which is necessary to improve outcomes of ALI, on 
the other hand [3–5].  
In an attempt to pursue our objective and alter ALI progression, attention was placed on 
two key elements of ALI pathophysiology that are common to all ALI patients: the effects 
of MV on the injured lung, and the development of a pulmonary inflammatory response 
following a lung insult. In order to perform our investigations, we utilized clinically 
relevant models of ALI (chapters 2, 3, and 4) resembling gastric acid aspiration and 
bacterial infection, two of the most common causes of direct lung injury [6]. Ex vivo MV 
was also utilized for part of our research, as ventilation can worsen lung injury and 
contribute to the severity of pulmonary and systemic inflammation which, in turn, is highly 
correlated with mortality in ALI [4, 7].  
In chapter 2, exogenous surfactant administration was investigated as a lung-targeted 
therapy potentially mitigating the pro-inflammatory effects of MV. The results from this 
chapter convincingly demonstrated that, even though exogenous surfactant was safe and 
overall well-tolerated, it was not effective in down-modulating the inflammatory response 
associated with ventilation in our models of ALI.  
These observations have led us to some important considerations. Firstly, the inability of 
exogenous surfactant to reduce lung and systemic inflammation in ALI may offer insight 
into the results of clinical trials in which surfactant treatment failed to improve mortality 
[8]. In light of the association between inflammation and mortality in ALI, however, it 
appeared necessary to broaden our research interest to identify other molecules, such as 
matrix metalloproteinase-3 (MMP-3), involved in inflammatory processes that could be 
targeted to limit the overwhelming inflammation in ALI. Secondly, while the results from 
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chapter 2 were consistent with previous experimental studies on exogenous surfactant [9, 
10], they conflicted with evidence suggesting that elevated endogenous surfactant has the 
potential to dampen the inflammation associated with different models of lung injury, while 
also preserving compliance and oxygenation [11, 12]. Therefore, there appeared to be 
complex inter-connections between pulmonary inflammation, lung surfactant, and 
respiratory mechanics, which we believed required further elucidation.  
As mentioned, the role MMP-3 was investigated in the context of LPS-induced and acid-
induced ALI (chapter 3) on the basis of a well described role for this protease in 
inflammation and repair [13]. Our findings confirmed a role for MMP-3 in the pulmonary 
inflammatory response associated with ALI, but also pointed out unanticipated sex 
differences in such response. Specifically, lack of Mmp3 expression reduced the 
concentrations of alveolar cytokines and chemokines following lung injury only in female 
mice, but not in males. Importantly, results from chapter 4 suggested that the mitigation 
of the inflammatory process observed in female, Mmp3-/- mice did not seem to correlate 
with improvements in physiological parameters related to respiratory mechanics and lung 
surfactant. The alteration observed in surfactant and lung mechanics were consistent with 
models of LPS-induced ALI, with no differences between genotypes. 
Based on the knowledge acquired from these series of studies, the purpose of this final 
chapter is to discuss observations not addressed in the previous chapters, and to briefly 
provide an overview of potential future directions that could complement and expand the 
findings of this thesis work.  
5.2. Future directions 
5.2.1. Exogenous surfactant as a vehicle for anti-inflammatory molecules 
The lack of efficacy of exogenous surfactant administration in our models of lung injury, 
and indeed in clinical trials of patients with ALI, has been disappointing. Nevertheless, 
these findings do not preclude the potential usefulness of this therapy in the treatment of 
lung injury. Exogenous surfactant can improve compliance and gas exchange, and these 
features are quite important within the pathogenesis of a disorder associated with 
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endogenous surfactant impairment such as ALI. As noted above, however, down-
regulation of the overwhelming inflammatory response is also required for optimal therapy. 
In this regard, combination therapy of surfactant with anti-inflammatory agents may be a 
novel therapeutic approach for ALI. In this approach, the ability of surfactant preparations 
to reach the more distal regions of the lung and spread across the alveolar surface will 
enhance the delivery of anti-inflammatory molecules to the distal areas of the injured lung 
[14].  
In the context of ALI, an anti-inflammatory molecule that could be utilized to improve the 
immuno-modulatory properties of exogenous surfactant is SP-A. This collectin has 
important functions in innate immunity and inflammation, and mice lacking SP-A 
expression experience higher lung concentrations of inflammatory mediators in models of 
lung injury [15, 16]. Importantly, SP-A is not present in exogenous surfactant preparations 
due to the purification process. The lack of SP-A in the exogenous surfactant utilized in 
our experiments may account, at least in part, for the absence of beneficial effects from 
surfactant treatment on inflammation observed in chapter 2. Future studies could therefore 
evaluate the efficacy of an exogenous surfactant preparation supplemented with SP-A in 
clinically relevant models of LPS-induced ALI or acid injury. Interestingly, both the 
oxidative stress, generated during acid injury, and LPS can activate TLR-4, a cell surface 
receptor expressed by alveolar macrophages and epithelial cells and involved in the 
production of pro-inflammatory cytokines [17, 18]. This is important, since SP-A has been 
shown to interact with TLR-4 preventing binding of smooth LPS, and it can also modulate 
TLR-4 expression and cellular localization [17, 19]. Supplementing exogenous surfactant 
with SP-A, therefore, could provide superior immuno-modulation associated with lower 
pulmonary and systemic inflammation, and consequently improved outcomes of ALI. It 
should be noted, however, that obtaining sufficient amounts of SP-A for clinical usage may 
be problematic as animal sources may lead to immunological issues, and synthesis of 
human SP-A, which is a complex glycosylated octadecamer, is currently not feasible. 
Despite the above limitations, it would be of interest to complement our findings from the 
study in chapter 2 by testing the effects of an exogenous surfactant-SP-A preparation on 
the inflammatory response subsequent to acid injury and MV. Considering that a recent 
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study suggested a role for SP-A in limiting the translocation of inflammatory mediators 
from the lung to the circulation [20], the isolated and perfused mouse lung set up would be 
ideal to deliver ex vivo MV. This system, in fact, allows for the collection and measurement 
of the lung-derived mediators released in the circulation throughout MV, alongside the 
monitoring of respiratory mechanics and lung inflammation. 
Whereas SP-A is an endogenous anti-inflammatory component of surfactant, it is also 
possible to supplement exogenous surfactant with other drugs to allow for optimal delivery. 
An important aspect of these approaches is to establish that the drug does not interfere with 
the function of surfactant and, vice versa, that the surfactant does not alter the properties 
of the anti-inflammatory drug. An example of this approach is currently being investigated 
in our laboratory as a potential therapy for the treatment of Pseudomonas Aeruginosa lung 
infection. In these studies, an exogenous surfactant is fortified with a small anti-microbial, 
anti-inflammatory peptide, capable of directly killing bacteria without causing antibiotic 
resistance [21]. Preliminary experiments appear promising, showing maintenance of 
surfactant and antimicrobial properties, safety and tolerability of this “fortified” surfactant, 
and excellent efficacy in the clearance of bacterial infection (B. Banaschewski, personal 
communication).  
Although a specific MMP-3 inhibitor has not yet been reported, a similar approach could 
be used if such compound became available. In this scenario exogenous surfactant could 
be used to deliver an MMP-3 inhibitor specifically to the injured lung, assuming that the 
surfactant-inhibitor preparation maintains both surfactant properties and pharmacological 
inhibition. Such an approach would overcome inherent limitations stemming from the use 
of a knock out mouse model. Importantly, this would allow us to study the effect of MMP-
3 inhibition on lung inflammation after the development of lung injury, thereby resembling 
a more clinically relevant scenario. 
5.2.2. Sex differences and the inflammatory response 
One of the most interesting observations stemming from this thesis work was related to the 
sex-differences observed in our models of ALI (chapters 3 & 4). Aside from the MMP-3 
related differences already discussed in chapter 3, a general examination of our data led to 
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the observation of different inflammatory responses to lung injury in wild type female 
compared to wild type male mice. As the a priori experimental questions in those studies 
were related to MMP-3, the female-male differences were not analyzed statistically; 
nonetheless, our results would suggested the presence of sexual dimorphism in the response 
to lung injury, which could be interesting to investigate in future studies. 
Male-female differences in immunity and inflammation have been described in several 
clinical and experimental studies. These investigations have demonstrated that, following 
infections, female mice have higher lung concentrations of inflammatory mediators, and 
mount a more robust innate and humoral responses than males [22–24]. This greater 
responsiveness in female subjects may favor a faster and more effective clearance of the 
invading pathogens than occurs in males, providing lower frequency of disease. With 
respect to pulmonary involvement, some studies have in fact shown greater susceptibility 
and incidence of respiratory infections [25], and greater risk of post trauma pneumonia in 
male patients compared to female patients [26, 27]. Interestingly, the risk of death among 
patients with post-injury pneumonia was greater in women than men [27]. Similar findings 
have also been described by Sakr and colleagues, who reported that female gender was an 
independent risk factor associated with death among patients with severe sepsis [28]. This 
clinical evidence suggests that the heightened immune response in females can be a 
‘double-edge sword’, as it can potentially exacerbate injury and lead to poorer outcomes. 
As pneumonia and sepsis are two of the most common causes of ALI, there is a good 
rationale for more experimental investigations aimed at exploring sex differences in ALI. 
Some indications in this regard can be found in our studies, in which a seemingly more 
robust pulmonary release of cytokines and chemokines such as IL-6, G-CSF, and TNF-α 
was observed in wild type females compared to males after LPS-induced lung injury, and 
was even more pronounced in mice exposed to acid instillation. To draw definitive 
conclusions and complement the observations of this thesis, the rigorous exploration of 
male-female differences in inflammation during ALI should be the objective of future 
studies. The first step would consist in exposing female and male mice to either LPS- or 
acid-induced ALI, and then analyzing outcomes of lung injury similar to the ones described 
throughout this thesis. Multiple cytokines and chemokines would be assayed in lavage 
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samples to evaluate sex differences in inflammation; moreover, time-course analyses could 
shed light onto possible variability in lung injury development. If the presence of sexual 
dimorphism in the inflammatory response to lung injury is confirmed, it would then be 
important to understand the underlying biological and physiological mechanisms, which 
could be related to the activities of steroid hormones [22]. To this end, outcomes of lung 
injury and inflammation would be measured in both sham and gonadectomized mice 
exposed to LPS and acid instillation. Subsequently, differences in the inflammatory 
response could be investigated following hormonal replacement. Altogether, these 
approaches would be helpful for unravelling the potential interactions between gonadal 
hormones and inflammatory processes in the pathogenesis of ALI. If such interactions truly 
occur, it will then be necessary to consider sex and gender as important variables within 
the treatment of this disease. 
5.2.3. MMP-3 and Surfactant  
While the above proposed studies would primarily focus on the effects of surfactant therapy 
or sex differences on the inflammatory response, the possibility that mediators of 
inflammation involved in ALI may affect surfactant (and therefore, lung function) should 
also be considered. This issue of the complex and elusive relationship between the different 
components – inflammation, surfactant, and lung mechanics – participating in the 
pathogenesis of ALI has been addressed in the context of the altered inflammatory response 
to injury in Mmp3-/- mice (chapter 4). One aspect, however, that has not been investigate 
yet is the specific interaction of the protease MMP-3 with surfactant proteins, such as       
SP-A. As mentioned, this collectin has an important role in innate host defense; however 
SP-A also contributes to the biophysical properties of surfactant, by reducing surfactant 
inhibition stemming from plasma protein or oxidative alterations [29, 30]. In this sense, 
alterations and/ or degradation of SP-A may not only affect the host defense properties, but 
can also lead to poorer biophysical function of surfactant, as shown by Malloy et al. in 
relation to the effects of P. Aeruginosa protease IV on SP-A [31].  
These interesting observations prompted preliminary in vitro experiments in our lab, 
performed through incubation of human SP-A with recombinant human MMP-3. Our 
preliminary results suggest that this protease can degrade free SP-A, but cannot cleave    
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SP-A when bound to surfactant lipids (data not shown). These initial findings are 
intriguing, and it would be interesting to validate them further through a series of in vitro 
experiments assessing, for example, the time course and dose response of SP-A 
degradation by MMP-3. Moreover, to answer the question of in vivo relevance of such 
potential interaction, lavage samples from Mmp3+/+ and Mmp3-/- mice exposed to lung 
injury could be analyzed to assess the state of SP-A degradation after injury-driven 
increases in lavage MMP-3, and the effect on overall surfactant function. Given the 
important roles of MMP-3 and SP-A in the modulation of the inflammatory response in 
ALI, and the biophysical alterations stemming from SP-A degradation, a more in-depth 
knowledge of such interplay could be beneficial to a better treatment of this disorder.  
5.3. Concluding remarks 
The Acute Lung Injury/ Acute Respiratory Distress Syndrome is a life- threatening 
condition with a mortality of 40%, high morbidity, and an incidence around 60-80 new 
cases for 100,000 persons every year. Despite many decades of intensive research, the main 
treatment in ALI is only supportive and involved in the disease pathogenesis.  
The findings presented in this thesis have contributed to the knowledge of ALI 
pathophysiology by: i) evaluating potential treatments in relation to outcomes of ALI 
clinically related to mortality; ii) identifying a potential target (MMP-3) in the regulation 
of the lung inflammatory response; iii) outlining possible sex-differences in the response 
to lung injury. Overall, these findings underscored the challenges faced in the identification 
of suitable targets and therapies for the treatment of this disorder. Such challenges result in 
part from the very complex and mutual influences between inflammation, lung surfactant, 
and overall lung function within the pathophysiology of ALI. Further experimental and 
clinical efforts, therefore, need to be channeled into ALI/ ARDS research to provide more 
effective treatment of this disorder and decrease mortality. 
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